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Abstract 
Fluorescent peptides are valuable tools for live-cell imaging due to the high specificity of peptide 
sequences for their biomolecular targets. When preparing fluorescent versions of peptides, labels 
need to be introduced at appropriate positions of the sequences to provide suitable reporters, while 
avoiding any impairment in the molecular recognition properties of the peptides. This protocol 
describes the preparation of the Trp-based fluorogenic amino acid Fmoc-Trp(C2-BODIPY)-OH and 
its incorporation into peptides for live-cell fluorescence imaging. Fmoc-Trp(C2-BODIPY)-OH 
contains a BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) fluorogenic core attached to Trp 
via a spacer-free C–C linkage; it thus mimics the molecular interactions of Trp but includes an 
environmentally sensitive label that enables fluorescence detection and wash-free imaging. Fmoc-
Trp(C2-BODIPY)-OH can be prepared in 3–4 d before being employed for the solid-phase synthesis 
of fluorogenic peptides (6–7 d). We have used this technology to prepare the fluorogenic 
antimicrobial peptide BODIPY-cPAF26 (3–4 d), which shows high chemical stability and minimal 
disruption of cellular activity when compared to the unlabeled sequence. We used BODIPY-
cPAF26 for wash-free imaging of fungal pathogens, including real-time visualization of Aspergillus 
fumigatus (5 d for culturing, 1-2 d for imaging). One major advantage of this procedure is the 
applicability to most peptide sequences, which enables the preparation of many peptide-based probes 
for enhanced fluorescence imaging. The procedure of this protocol covers the chemical synthesis of 
the fluorogenic amino acid Fmoc-Trp(C2-BODIPY)-OH, the preparation of the labeled antimicrobial 
peptide BODIPY-cPAF26 and their spectral and biological characterization as live-cell imaging 
probes for different fungal pathogens. 
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INTRODUCTION 
Peptides are excellent molecular frameworks for the generation of imaging agents because they bind 
with high affinity and specificity to their targets. However, most peptides cannot be directly 
visualized using fluorescence imaging as they lack proper reporter groups and need to be modified 
with fluorophores or reactive tags for further derivatization.1 A milestone in peptide and protein 
labeling has been the development of genetically encoded unnatural amino acids, which can be 
incorporated in response to nonsense or frameshift codons to embed suitable bioorthogonal groups at 
specific sites of peptides and proteins.2 Recent advances that have driven a progress in the field of 
fluorescence imaging include the genetic encoding of norbornene amino acids, which can rapidly and 
specifically couple to tetrazine-containing fluorophores for protein labeling,3 or the optimization of 
orthogonal variants of the inverse-electron-demand Diels-Alder cycloaddition reaction for dual color 
live-cell imaging and super-resolution microscopy.4, 5 
In addition to synthetic biology strategies, many unnatural amino acids are available as building 
blocks to expand the chemical diversity within peptide sequences using solid-phase peptide synthesis 
(SPPS).6, 7 These building blocks include unnatural amino acids with chemical groups amenable for 
two-step labeling processes (e.g. azides, alkynes, and alkenes). Once peptides containing these amino 
acids are synthesized, they are coupled to a suitable fluorophore (for instance, using ‘click’ 
chemistry), and the excess labeling agent is washed out prior to image acquisition. This approach has 
proven useful for many different applications,8-11 although the need for washing steps might hamper 
its implementation in in vivo and real-time imaging. Recent progress has involved the preparation of 
the bioorthogonal fluorophores with bright fluorescence emission after the conjugation reaction, 
which leads to a reduction in fluorescence background and a minimization of the washing steps.12-14 
Moreover, further development of synthetic methodologies to diversify amino acids and peptides15-17 
will create opportunities for direct fluorescence labeling and in situ imaging studies.  
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Most commonly, peptides are readily labeled by attaching a fluorophore to a residue in the peptide 
sequence, yielding fluorescent conjugates that can be directly used for imaging. However, 
fluorophores have bulky structures that can impair the molecular recognition properties of the native 
peptide; it is, therefore, important to introduce fluorophores at appropriate positions within the amino 
acid sequence. Most of them are incorporated into peptides by reaction with terminal or side-chain 
chemical groups (e.g. amines, carboxylic acids, and thiols) from polar residues or through chemical 
spacers.18-20 Since these modifications can disrupt the hydrogen bonding pattern with respect to the 
original peptide and have a detrimental effect on the biological properties of the fluorescent 
conjugate,21 there is a demand for new technologies to incorporate fluorophores into peptides without 
affecting their inherent activity and, ideally, with suitable spectral properties for live-cell imaging 
applications. 
Overview of the procedure 
A schematic flowchart outlining the different sub-sections of the Procedure described in this protocol 
and their expected time requirement is reported in Figure 1. We have developed a new methodology 
to synthesize fluorogenic peptides that relies on a unique Fmoc-Trp(C2-BODIPY)-OH amino acid 
(1),22 which can be prepared by attaching a BODIPY fluorophore to the C2 position of Trp via a 
spacer-free C–C linkage (Steps 1–35). Amino acid 1 mimics the molecular interactions of native Trp, 
and it possesses a fluorogenic label that can be used for live-cell imaging. Compound 1 shows high 
chemical stability, as we could prove by conducting the test described in Steps 36–37 (a quality 
control test that could be implemented before using a stock of compound 1 that has been stored as 
described in the Procedure), excitation and emission spectra in the visible range, and remarkable 
fluorescence enhancement in hydrophobic environments (i.e. when the peptide is binding to its 
target), which facilitates wash-free imaging experiments. We have validated the usefulness of 1 as a 
precursor of peptide-based imaging probes by derivatizing the antimicrobial peptide PAF26,23 which 
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shows high affinity and selectivity for fungal cells. We detail in the Procedure the synthesis of the 
fluorogenic analogue of PAF26 (BODIPY-cPAF26) by conventional SPPS, simply using 1 instead 
of natural Trp (Steps 38–89). We have also recently employed the amino acid 1 for the preparation of 
cyclic peptides as fluorescent reagents for imaging apoptotic bodies.24 BODIPY-cPAF26 shows 
high resistance to proteolysis (which could be tested as described in Steps 90–94), strong fluorogenic 
response in hydrophobic environments (see also procedure reported in Steps 95–106) and no 
impairment of the activity and selectivity of the native peptide in human and fungal cells (see tests 
described in Steps 107–131 and 132–162, respectively). All these tests represent a comprehensive 
panel of characterization experiments that can be readily implemented in other peptide sequences 
modified with the fluorogenic amino acid 1. Finally, we describe the use of BODIPY-cPAF26 for 
fluorescence live-cell imaging of several fungal pathogens (Steps 163–206) and real-time imaging of 
Aspergillus fumigatus (Steps 207–219), one of the most life-threatening human fungal pathogens. 
These imaging experiments should be considered as a template set of directions to be modified for 
the readers in their experiments of choice, which may vary depending on the instrumentation (e.g. 
confocal microscope) and cell systems used.   
Figure 1.  
Advantages and limitations of the procedure 
A major advantage of this procedure is its general applicability, as it can be used to prepare 
fluorogenic analogues of most peptide sequences. Amino acid 1 is compatible with Fmoc-based 
SPPS protocols, tolerates standard deprotection and coupling conditions as well as mild acid-based 
deprotection strategy, without any observable degradation of the BODIPY fluorophore.25, 26 Notably, 
careful design of the protecting group scheme is needed to ensure full orthogonality with the 
BODIPY structure; for instance, in the synthesis of BODIPY-cPAF26, we used Fmoc-Lys(Z)-OH 
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instead of Fmoc-Lys(Boc)-OH and Fmoc-Arg(NO2)-OH instead of Fmoc-Arg(Pbf)-OH to avoid any 
acid-sensitive protecting groups.   
Importantly, the exact impact of the Trp-BODIPY on the biomolecular properties of the labeled 
peptides needs to be examined on a case-by-case basis. Although most of the labeled bioactive 
peptides examined so far have shown similar activity patterns to their unlabeled, natural 
counterparts,22 the introduction of Trp-BODIPY may prove detrimental to the activity of other 
peptides, and we recommend the readers to run proper tests (as those described in Steps 132-162) to 
compare the functional properties of labelled vs non-labelled peptide sequences. 
Regarding spectral properties, 1 has both excitation and emission maximum wavelengths in the green 
region of the visible spectra (λexc. ~500 nm, λem. ~520 nm), which makes it ideally suited for 
conventional GFP (Green Fluorescent Protein)/ FITC (Fluorescein isothiocyanate) filters found in 
most spectrophotometers, flow cytometers, confocal microscopes and other imaging equipment. This 
characteristic is an important advantage with respect to naphthalene-, coumarin- and dansyl-based 
fluorescent amino acids that have been introduced as labels in peptides through SPPS.27-30 Once 
inserted into peptides, these fluorogenic groups display shorter excitation and emission wavelengths 
than 1, with relatively long Stokes shifts. Extensive work in this field has been performed by 
Imperiali and co-workers, who developed environmentally-sensitive fluorescent amino acids as 
reporters of protein–protein interactions.31-34 These amino acids are mostly based on the 
naphthalimide scaffold and display remarkable fluorescence enhancements in hydrophobic 
environments, with excitation wavelengths around 400–450 nm and extinction coefficients around 
103 to 104 M-1cm-1.35, 36 Although the emission enhancement of 1 in hydrophobic environments might 
be slightly lower than that of naphthalimide-based amino acids, its high extinction coefficient (i.e. 
around one order of magnitude higher than its counterparts) results in overall stronger brightness. 
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Unlike the case of peptides containing unnatural amino acids with reactive orthogonal groups, the 
strong fluorogenic behavior of 1 makes it possible for the relevant labeled peptides to be used 
directly for live-cell imaging in wash-free conditions and without any additional labeling steps. This 
feature represents a major advantage in imaging experiments, where dynamic processes in living 
cells need to be monitored in real time.  
The main limitation of the present protocol is that it can be implemented only to label the peptides or 
small proteins that are currently accessible via semi-synthetic approaches or by Fmoc-based SPPS.  
Experimental design and crucial parameters 
Fmoc-Trp(C2-BODIPY)-OH: chemical synthesis, fluorescence properties and shelf life. We 
designed the synthesis of 1 so as to obtain the Fmoc-protected compound, which can be readily used 
for the synthesis of medium-sized peptides by conventional SPPS. The BODIPY fluorophore was 
selected because of its compact structure and excellent spectral photophysical properties.37, 38 We 
decided to incorporate it into the C2 position of Trp in a spacer-free C–C linkage to maintain the 
main recognition features of the labeled peptides (e.g. charge balance, overall polarity, and H-bond 
pattern). The retrosynthetic analysis of the amino acid 1 involves the arylation of the m-iodophenyl-
BODIPY (3) on the unsubstituted C2 position of Fmoc-Trp-OH (2) by Pd-catalyzed C–H 
activation39-41, using an approach we recently developed (Figure 2).16 The m-iodophenyl-BODIPY 
(3) can be prepared by acid-catalyzed condensation of the m-iodobenzaldehyde (4) with two 
equivalents of 2,4-dimethylpyrrole (5), followed by 2,3-dichloro-5,6-dicyano-p-benzoquinone 
oxidation and BF3 complexation. Notably, all the starting materials needed for the synthesis of 1 (i.e. 
compounds 2, 4 and 5) are commercially available. 
Figure 2. 
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Following similar reported procedures,42 compounds 4 and 5 are mixed in conditions of 
trifluoroacetic acid (TFA) catalysis to yield the expected adduct with loss of a water molecule after 
stirring at room temperature for 22 h in anhydrous dichloromethane. Notably, in our hands, the 
synthetic yields did not significantly improve in the presence of dehydrating agents, such as 4Å 
molecular sieves. Next, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) is added to the crude 
mixture with continuous stirring for 15 min, followed by addition of an excess of triethylamine and 
BF3·Et2O. The resulting dark green solution is stirred at room temperature for 4.5 h to produce 
compound 3 as the major product in a crude form. Liquid–liquid extraction followed by flash 
chromatography over silica gel affords compound 3 in ~30% yield (over the 3 steps). Of note, we 
observed slightly lower synthetic yields when this reaction was scaled up over 200 mg scale.  
Next, the m-iodophenyl-BODIPY 3 is subjected to Pd-catalyzed arylation of Fmoc-Trp-OH (2) to 
afford the desired Fmoc-Trp(C2-BODIPY)-OH (1) (Figure 3a).43-45 The amino acid 2, a slight excess 
of m-iodophenyl-BODIPY 3 (1.5 eq.), AgBF4 (1.0 eq.), TFA (1.0 eq.) as the acid source, and 
catalytic Pd(OAc)2 (0.05 eq.) are dissolved in N,N-dimethylformamide (DMF) and subjected to 
microwave irradiation for 20 min at 80 ºC. In our hands, 1 is isolated by normal-phase 
chromatography over silica gel in ~70% yield. Although our attempts to scale-up this reaction 
resulted in decreased yields, parallelization of the procedure is convenient and reproducible. Please 
note that conducting the reaction described above (Figure 3a) under conventional heating requires 
higher temperatures and longer reaction times than those mentioned for microwave-based synthesis, 
and it leads to the formation of very complex crude mixtures, due to the limited stability of the Fmoc 
and BODIPY groups in the mentioned conditions. These limitations make the preparation of 1 
feasible only under microwave irradiation. 
Figure 3.  
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Compound 1 displays excitation and emission maximum wavelengths in the green region of the 
visible spectrum (λexc.: 503 nm, λem.: 517 nm; Figure 3b). These spectral properties are optimal for its 
use in most spectrophotometers, flow cytometers and confocal microscopes, since these are generally 
equipped with excitation sources and emission filters matching the spectral properties of GFP or 
FITC (λexc. ~ 490 nm, λem. ~ 520 nm). Furthermore, we examined the chemical integrity of 1 in 
different conditions to determine the optimal storage conditions as well as its shelf life (Figure 3c 
and Supplementary Figures 1-2).  Amino acid 1 is completely stable when stored in the dark as a 
solid, even at room temperature for up to 4 months (i.e. this was the longest time point measured at 
the time of submission). With respect to the common solvents used in peptide synthesis, we 
determined that 1 is fully stable in both dichloromethane and methanol solutions for up to 4 months, 
but loses the Fmoc group when it is stored in DMF for long periods of time at room temperature 
(13% degradation after 1 month, 45% after 2 months, and 97% after 4 months), in agreement with 
previous reports on the stability of Fmoc-protected amino acids.46 Moreover, even though we did not 
observe any degradation of the BODIPY core upon exposure to daylight, we recommend storing 1 
and its derivatives in the dark as a precautionary measure. Altogether, these results confirm that 1 
can be shipped and employed as most Fmoc-protected amino acids, and even stored for several 
months in DMF at 4 ºC or −20 ºC. 
Fluorogenic antimicrobial peptides: solid-phase synthesis, fluorogenic behavior and biological 
characterization. Given their selectivity for microbes over mammalian cells, fluorescent 
antimicrobial peptides are promising tools for imaging infectious pathogens.47, 48 Our research group 
and others have studied the mechanism of action of Peptide AntiFungal 26 (PAF26), an 
antimicrobial hexapeptide with high affinity for fungal cells. PAF26 (H-RKKWFW-NH2) has a short 
and conserved sequence with hydrophobic and cationic domains that are indispensable for its cellular 
activity.49 We envisioned that fluorogenic PAF26 analogues, in which natural Trp is replaced by 1, 
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would retain the activity and selectivity for fungal cells of the original sequence, while incorporating 
a suitable label for fluorescence imaging. Furthermore, since cyclic peptides show increased 
resistance to proteases50 (such as those secreted by infective pathogens), we designed the synthesis of 
a cyclic fluorogenic peptide (BODIPY-cPAF26, Figures 4 and 5a) based on the sequence of PAF26. 
BODIPY-cPAF26 is synthesized using 2-chlorotrityl polystyrene resin and Fmoc-based SPPS 
protocols (Figure 4).  
Figure 4. 
In the Procedure, as building blocks are used the amino acid 1 as well as Fmoc-Gly-OH, Fmoc-Phe-
OH, Fmoc-Trp-OH, Fmoc-Lys(Z)-OH, and Fmoc-Arg(NO2)-OH, which are fully mutually 
orthogonal in the mildly acidic cleavage conditions (TFA: DCM = 1: 99) and enable the isolation of 
the fully protected cyclic peptide without damaging the BODIPY core. In the synthesis of BODIPY-
cPAF26, all non-labeled amino acids are incorporated at a concentration of 3 eq, using conventional 
N,N’-diisopropylcarbodiimide (DIC) and OxymaPure, whereas 1 is incorporated using a moderate 
excess (1.5 eq.), and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate, 1-
hydroxybenzotriazole, and N,N-diisopropylethylamine (DIPEA) as coupling reagents. Acidic 
cleavage produces the protected linear peptide, which is subsequently cyclized by treatment with 
DIPEA and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) in DMF in over 80% yield after precipitation in H2O. Final 
hydrogenolysis and purification by semi-preparative HPLC affords the BODIPY-cPAF26 peptide in 
very high purity (> 99%). Typically, the overall yield for the synthesis of the peptide BODIPY-
cPAF26 is 20–25% (~10 mg product per ~45 mg of resin). 
We have compared the antimicrobial activity of PAF26 to that of BODIPY-cPAF26, and determined 
their IC50 values for two different fungal species, Neurospora crassa and Aspergillus fumigatus. N. 
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crassa is an experimental model organism for filamentous fungi,51 whereas A. fumigatus is a fungal 
pathogen causing multiple human diseases, the most lethal of which is invasive pulmonary 
aspergillosis (IPA), an infection that causes around 200,000 deaths per year worldwide.52 Notably, 
BODIPY-cPAF26 did not impair the antifungal activity of the original sequence, and it displayed 
slightly higher affinity for both fungal species than the unlabeled PAF26 peptide (Figure 5b and 
Supplementary Table 1). We also examined the fluorescence response of BODIPY-cPAF26 in 
phospholipid liposomes, which mimic the microenvironment of cell membranes. Fluorescence 
spectra of BODIPY-cPAF26 were recorded upon incubation with liposome suspensions of 
phosphatidylcholine:cholesterol (7:1) in phosphate buffer saline with increasing concentrations of 
phosphatidylcholine. As shown in Figure 5c, BODIPY-cPAF26 displayed strong fluorogenic 
behavior, with quantum yields slightly over 30% after binding to phospholipid membranes 
(Supplementary Table 2). Finally, we evaluated the cytotoxicity of BODIPY-cPAF26 in A549 lung 
epithelial cells as an indication of their poor affinity for human cells. We did not detect significant 
differences in the viability of A549 cells with or without incubation of BODIPY-cPAF26 for several 
hours, even at relatively high concentrations (Figure 5d). Altogether, these results corroborate the 
suitability of the fluorogenic amino acid 1 as a Trp surrogate with minimal interference in the 
recognition properties of peptide sequences, which provides a suitable reporter to visualize molecular 
interactions using fluorescence-based techniques. 
Figure 5. 
Since imaging infection sites using peptide-based probes can be hindered by the presence of 
proteolytic enzymes, we examined the chemical integrity of BODIPY-cPAF26 in proteolytic 
environments, and compared its degradation to the unlabeled PAF26. Both peptides were incubated 
at the same concentration in a protease cocktail for over 24 h, and time-course analysis was 
performed by HPLC-MS. Being a cyclic peptide, BODIPY-cPAF26 showed high stability to 
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proteases, with marginal degradation after 24 h incubation (Supplementary Figures 3-4). In the same 
experimental conditions, the unlabeled linear peptide PAF26 was mostly degraded with only 20% of 
intact peptide left after 24 h. 
Live-cell fluorescence imaging of fungal pathogens, including A. fumigatus. In view of the 
excellent properties of BODIPY-cPAF26 as a highly stable and fluorogenic peptide to report the 
interaction with fungal cells, we employed it for live-cell imaging of different fungal species. In 
addition to N. crassa and A. fumigatus, we also examined the staining of BODIPY-cPAF26 in other 
fungal pathogens, namely Cryptococcus neoformans, Fusarium oxysporum and Candida albicans. 
BODIPY-cPAF26 showed bright staining in all the species, suggesting a potential common target 
for different fungi (Figure 6). Notably, the fluorogenic behavior of BODIPY-cPAF26 enables live-
cell imaging by simple incubation with the cells, in a single step and without the need for any 
washing protocols. This procedure represents an important advantage over imaging procedures with 
fluorescent peptides that are labeled using alternative procedures (e.g. ‘click’ fluorophores used in 
two-step labeling procedures or ‘always-on’ fluorophores that require washing). 
Figure 6.  
Since A. fumigatus is the fungal pathogen responsible for IPA, a life-threatening disease in 
immunocompromised patients,52 we performed further studies to visualize the dynamic interaction 
between BODIPY-cPAF26 and living cells of A. fumigatus. Germlings of A. fumigatus were pre-
incubated with a red fluorescent probe that first stained the whole plasma membrane and then 
intracellular vacuoles. Before the red membrane stain was internalized, we added BODIPY-cPAF26 
to the cells and acquired time-course fluorescence images at high magnification to overlay the green 
signal from BODIPY-cPAF26 and the red signal from the counterstain (Figure 7 and Supplementary 
Video 1). After 20 seconds of its addition, BODIPY-cPAF26 stained the plasma membrane in the 
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apical region of the germling cells. In the following minutes, the green fluorescence signal moved 
towards the base of the germling, while the red counterstain started to accumulate in intracellular 
vacuolar organelles. These results validate our procedure using the amino acid Fmoc-Trp(C2-
BODIPY)-OH as an efficient chemical strategy to prepare fluorogenic peptides for enhanced 
fluorescence live-cell imaging without any washing steps. As a proof-of-concept, we have 
synthesized BODIPY-cPAF26 as a stable, cyclic antimicrobial peptide for imaging dynamic 
processes in living fungal pathogens.   
Figure 7.  
  
14 
MATERIALS 
! CAUTION All organic solvents and bases are flammable, toxic and harmful by inhalation, ingestion or skin contact. Coupling reagents and additives 
are flammable and irritant. For these and other toxic, corrosive and/or irritant reagents, laboratory coat, gloves and safety goggles should be worn. 
All synthetic operations should be performed in a chemical fume hood. 
 
REAGENTS 
•  Deionized water (dH2O) 
•  Sterile water (Baxter, cat. no. UKF7114, stored at room temperature (r.t.)) (r.t.: 20–25 °C) 
• Celite (Sigma-Aldrich, cat. no. 22138, stored at r.t.) 
• Silica gel 60 Å (Carlo Erba, cat. no. P2000027, stored at r.t.) 
• 2-Chlorotrityl chloride polystyrene resin (2-CTC-PS; Iris Biotech GMBH, cat. no. BR-1060, stored at r.t.) 
• Dichloromethane (DCM; Scharlab, cat. no. CL0331, stored at r.t.)  
• Anhydrous dichloromethane (anhydrous DCM; Sigma-Aldrich, cat. no. 494453, stored at r.t.)  
• Hexane (Scharlab, cat. no. HE0228, stored at r.t.) 
• Toluene (J.T. Baker, cat. no. 8078, stored at r.t.) 
• Ethyl acetate (EtOAc; Scharlab, cat. no. AC0143, stored at r.t.) 
• N,N-Dimethylformamide (DMF; Panreac Applichem, cat.no. 161785.1612, stored at r.t.)  
• Anhydrous N,N-Dimethylformamide (anhydrous DMF; Sigma-Aldrich, cat.no. 227056, stored at r.t.) 
• N,N-Diisopropylethylamine (DIPEA; Sigma-Aldrich, cat. no. 496218, stored at r.t) 
• Nα-(9-Fluorenylmethyloxycarbonyl)-L-glycine (Fmoc-Gly-OH; Iris Biotech GMBH, cat. no. FAA1050, stored at 4 °C) 
• Nα-(9-Fluorenylmethyloxycarbonyl)-L-tryptophan (Fmoc-Trp-OH; Sigma-Aldrich, cat. no. 47637, stored at 4 °C)  
• Nα-(9-Fluorenylmethyloxycarbonyl)-L-phenylalanine (Fmoc-Phe-OH; Iris Biotech GMBH, cat. no. FAA1175, stored at 4 °C)  
• Nα-(9-Fluorenylmethyloxycarbonyl)- Nε-(benzyloxycarbonyl)-L-lysine (Fmoc-Lys(Z)-OH; Sigma-Aldrich, cat. no. 47577, stored at 4 °C)  
• Nα-(9-Fluorenylmethyloxycarbonyl)- Nω-(nitro)-L-arginine (Fmoc-Arg(NO2)-OH; Sigma-Aldrich, cat. no. 47527, stored at 4 °C)  
• Methanol (MeOH; Sigma-Aldrich, cat. no. 65542, stored at r.t.) 
• Acetonitrile (ACN; Scharlab, cat. no. AC0333, stored at r.t.)  
• Formic acid (Merck Millipore, cat. no. 100264, stored at r.t.) 
• Trifluoroacetic acid (TFA; Fluorochem, cat. no. 001271, stored at r.t.) ! CAUTION Toxic and corrosive  
• Piperidine (Carlo Erba; cat. no. P0660216, stored at r.t.)  
• Ethyl (hydroxyimino)cyanoacetate (OxymaPure; Luxembourg Bio Technologies, stored at r.t.) 
• (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP; Novabiochem, cat. no. 8510090, stored at 4 °C) 
• 1-Hydroxybenzotriazole (HOBt; Carbosynth, cat. no. FH02087, stored at 4 °C) ! CAUTION Explosive, if dry. Always use as the monohydrate form and 
keep away from heat sources. 
• (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU; Fluorochem, cat. no. 023926, stored at 4 
°C) ! CAUTION Irritant 
• Hydrogen (H2) ! CAUTION It is extremely flammable; it can form explosive mixture with air and may react violently with oxidants. 
• Palladium hydroxide on activated charcoal (Pd(OH)2-C; Sigma-Aldrich, cat. no. 76063, stored at r.t.) 
• 3-Iodobenzaldehyde (Apollo Scientific, cat. no. OR8221, stored at 4 °C) ! CAUTION Irritant 
• 2,4-Dimethylpyrrole (Sigma-Aldrich, cat. no. 390836, stored at 4 °C) ! CAUTION Irritant  
• 2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ; Sigma-Aldrich, cat. no. D60400, stored at 4 °C) ! CAUTION Toxic 
• Triethylamine (TEA; Sigma-Aldrich, cat. no. T0886, stored at r.t.) 
• Boron trifluoride diethyl etherate (BF3·OEt2; Sigma-Aldrich, cat. no. 175501, stored at 4 °C) ! CAUTION Flammable, toxic and corrosive 
• Anhydrous sodium sulfate (Na2SO4 anh; Panreac Applichem, cat.no. 191716.1211, stored at r.t.) 
• Palladium acetate (Pd(OAc)2; Sigma-Aldrich, cat. no. 205869, stored at r.t.) ! CAUTION Irritant and causes skin corrosion 
• Silver tetrafluoroborate (AgBF4; Sigma-Aldrich, cat. no. 208361, stored at r.t.) ! CAUTION Corrosive and harmful. 
• Ethanol absolute (EtOH, VWR, cat. no. 20821.330, stored at r.t.) 
• Sodium phosphate dibasic heptahydrate (Sigma Aldrich, cat. no. S9390, stored at r.t.) 
• Citric acid monohydrate (Sigma Aldrich, cat. no. C-1909, stored at r.t.) 
• Sodium hydroxide (Fisher, cat. no. S/4840/60, stored at r.t.) 
• N,N′-Diisopropylcarbodiimide (DIC; Sigma-Aldrich, cat.no. D125407, stored at 4 °C) 
• Fluorescein (Sigma-Aldrich, cat. no. 32615, stored at r.t.) 
• Protease from Streptomyces Griseus type XIV (protease type XIV, Sigma Aldrich, cat. no. P5147, stored at -20 °C) 
• PAF26 peptide (H-RKKWFW-NH2, Genscript, lot no. P10271403, stored at 4 °C) 
• Dimethyl sulfoxide for molecular biology (DMSO, Sigma Life Sciences, cat. no. D8418, stored at r.t.) 
• Ca2+-free Dulbecco’s Phosphate Buffered Saline (Ca2+-free DPBS; Gibco, Life Technologies, cat. no. 14040-091, stored at r.t.) 
• MTT reagent (Trevigen, MTT Cell Proliferation assay kit, cat. no. 4890-25-01; stored at. 4 °C) 
• Detergent reagent for MTT assay (Trevigen, MTT Cell Proliferation assay kit, cat. no. 4890-25-02, stored at r.t.) 
• RPMI Cell Media 1640 (Gibco, Life Technologies, cat. no. 31870-025, stored at 4 °C) 
• Phosphatidylcholine: cholesterol (7: 1) liposomes (Clodronate Liposomes, 10 mL PBS liposomes, stored at 4 °C) 
• Heat inactivated Fetal Bovine Serum (FBS; Gibco Life Technologies, cat. no. 10500-064, stored at -20 °C) 
• Penicillin-Streptomycin (Pen Strep; Gibco Life Technologies, cat. no. 15140-122, stored at -20 °C) 
• L-Glutamine (L-Glu; Gibco Life Technologies, cat. no. 25030-024, stored at -20 °C) 
• 0.05% (w/v) Trypsin-Ethylenediaminetetraacetic acid (EDTA) (Gibco Life Technologies, cat. no. 25300-054, stored at -20 °C) 
• Sucrose (Sigma-Aldrich, cat. no. S0389, stored at r.t.) 
• Oxoid™ Agar technical (Thermo Fisher Scientific, cat. no. LP0013B, stored at r.t.)  
• Sodium citrate dihydrate (Sigma-Aldrich, cat. no. 71402, stored at r.t.) 
• Potassium phosphate monobasic (KH2PO4; Sigma-Aldrich, cat. no. P5655, stored at r.t.) 
• Ammonium nitrate (NH4NO3; Fluka, cat. no. A9642, stored at r.t.) 
• Magnesium sulfate heptahydrate (MgSO4 · 7 H2O; Sigma-Aldrich, cat. no. M2773, stored at r.t.) 
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• Calcium chloride dihydrate  (CaCl2 · 2H2O; Sigma-Aldrich, cat. no. C3306, stored at r.t.) 
• Citric acid (Sigma-Aldrich, cat. no. P5655, stored at r.t) 
• Zinc sulfate heptahydrate  (ZnSO4 · 7 H2O; Sigma-Aldrich, cat. no. Z0251, stored at r.t.) 
• Ammonium iron (II) sulfate hexahydrate ((NH4)2Fe(SO4)2 · 6 H2O; Sigma-Aldrich, cat. no. 09719, stored at r.t.) 
• Copper (II) sulfate pentahydrate (CuSO4 · 5 H2O; Sigma-Aldrich, cat. no. C8072, stored at r.t.) 
• Manganese (II) sulfate monohydrate (MnSO4 · H2O; Sigma-Aldrich, cat. no. M7899, stored at r.t.) 
• Boric acid (H3BO3; Sigma-Aldrich, cat. no. B6768, stored at r.t.) 
• Sodium molybdate dihydrate (Na2MoO4 · 2 H2O; Sigma-Aldrich, cat. no. M1651, stored at r.t.) 
• D-biotin (SUPELCO, cat. no. 47868, stored at 4 oC) 
• Glycerol (UltraPure™ Thermo Fisher Scientific, cat. no. 15514011, stored at r.t.)  
• Oxoid™ Sabouraud (SAB) dextrose liquid medium (Thermo Fisher Scientific, cat. no. CM0147, stored at r.t.) 
• Oxoid™ Sabouraud dextrose agar (SAB agar; Thermo Fisher Scientific, cat. no. CM0041, stored at r.t.) 
• Oxoid™ Potato dextrose agar (PDA; Thermo Fisher Scientific, cat. no. CM0139, stored at r.t.) 
• Potato dextrose broth (PDB; CONDA, cat. no. 1261, stored at r.t.) 
• Tween80 (Sigma-Aldrich, cat. no. P4780, stored at r.t.) 
• Tetramethylaminorhodamine-labelled PAF96 red counterstain (TAMRA-PAF96, TAMRA-AAAWFW-NH2; Genscript, stored at 4 °C) 
• A549 cells (ATCC, cat. no.: A549-ATCC CCL-185, stocks stored at -80 °C or -125 °C) 
• Neurospora crassa (FGSC, cat. no: FGSC 2489, strain 74-OR23-1V A, stored at -80 °C) 
• Aspergillus fumigatus (FGSC, cat. no.: FGSC A1163, strain CEA10, stored at -80 °C) 
• Cryptococcus neoformans (FGSC, cat. no.: FGSC 9487, strain H99, stored at -80 °C)  
• Fusarium oxysporum (FGSC, cat. no.: FGSC 9935, strain 4287, stored at -80 °C) 
• Candida albicans (ATCC, cat. no.: ATCC MYA2876, strain SC5314, stored at -80 °C) 
 
LABWARE AND EQUIPMENT 
•  Set of micropipettes (200-1000, 20-200 and 2-20 µL, Gilson) 
•  Pipette disposable universal tips (5-200 and 100-1000 µL, Daslab) 
•  Teflon stick 
•  6 mL polystyrene syringes cartridge with polyethylene porous disc (Agilent technologies) 
•  Spatula 
•  Timer 
•  50 mL polypropylene centrifuge tubes with screwcaps (VWR) 
• 15 mL polypropylene conical tubes (Corning) 
• 75 cm2 polystyrene cell culture flasks with canted neck (Corning, cat. no. 430720U) 
• 50 mL polystyrene disposable pipette basins (Fisherbrand, cat. no. 13-681-502) 
• Pipet aid PIPETBOY acu 2 (Integra, cat. no. 155000) 
•  96-well tissue culture plates, black, flat bottom with lid (Falcon, cat. no. 353376) 
•  96-well cell culture plates, flat bottom with low-evaporation lid, polystyrene (Costar, cat. no. 3595) 
•  Plastic syringes (Terumo or BD Plastipak, hypodermic Syringes without needle) 
•  1-mL glass syringes (Thomas Scientific)  
•  Needles (BD Microlance, 21 G) 
•  1.5 mL microcentrifuge tubes (VWR) 
•  Plastic (Agilent technologies) and Teflon (Biotage) stopcocks 
•  Glass vials (7 x 50 mm, VWR) 
•  Filters (0.45 µm, PVDF hydrophilic) (Millipore) 
•  Latex (VWR) or nitrile gloves (GEN-X, Kisher Biotech) 
•  Plastic septa (Φ 14.9 mm and Φ 30.7 mm, Saint-Gobain Performance Plastics) 
•  Parafilm  
•  Round-bottom flasks 
•  Plastic funnels 
•  Separatory funnels 
•  Conical flasks 
•  Glass Pasteur pipettes (VWR) 
•  Plastic Pasteur pipettes (VWR) 
•  Cotton 
•  Stirring bars 
•  Aluminium TLC plates (Silica gel 60 F254 20 × 20 cm, Merck KGaA) 
•  Fritted glass funnels (Φ 55 mm, grade 4, Duran) 
•  Adapter flask funnels 
•  10 mL capped reaction vessels (CEM, cat. no. 19.909050) 
•  CEM Discover SP microwave synthesizer with Synergy software (CEM) 
•  RediSep Rf frits for RediSep 25 g cartridges (Teledyne ISCO, cat. no. 60-5237-053)  
•  Syringe filters (25 mm polypropylene 0.45 µm, Phenex, cat. no. AF7-1101-12) 
•  Columns for ISCO flash chromatography: Silica HP RediSep Rf 40 g flash columns, cat. no. 69-2203-347; Silica HP RediSep Rf 30 g  
 flash column, cat. no. 69-2203-345 (Teledyne ISCO) 
•  60 mL polystyrene syringe cartridge with polyethylene porous disc for flash chromatography (Agilent technologies) 
•  CombiFlash purification system (Teledyne ISCO) 
•  Rotary evaporator (Laborota 4003, Heidolph) 
•  Analytical balance (AB204-S, Mettler Toledo) 
•  Orbital platform shaker (Unimax 1010, Heidolph) 
•  Magnetic stirrer (IKA RCT Basic S1 Werke Safety Control Magnetic Hotplate Stirrer) 
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•  UBD heating block (Grant) 
•  Hand-held UV lamp (6W, UVP) 
•  pH-meter (CyberScan pH 510, Eutech) 
•  Termoblock shaker (Eppendorf Thermomixer) 
•  Vortex mixer (BV1000, Benchmark Scientific) 
•  Multichannel electronic pipette (Rainin E4 XLS 12-channel, 20-200 µL LTS, Mettler-Toledo) 
•  Multichannel electronic pipette tips (Rainin Tips LTS, 200 µL, GP-L200F, Mettler-Toledo) 
•  Cell counter (ChemoMetec A/S, Nucleocounter) 
•  Lyophilizer (Virtis Freezemobile) 
•  Centrifuge for peptide synthesis (Beckman Allegra 21R) 
•  Centrifuge for cell culture (Sanyo Mistral 3000i) 
•  Sonicator (Clifton Ultrasonic bath) 
•  Water bath (Aqualine AL18, Lauda) 
•  Vacuum pump 
•  High-performance liquid chromatography system (HPLC): Waters 2695 separations module, Waters 2996 photodiode array detector 
•  HPLC system coupled to mass spectrometer (HPLC-MS):  Waters 2695 separations module, Waters 2996 photodiode array detector. The MS 
spectrometer contains an electrospray ionization source (Micromass ZQ) and the MassLynx 4.1 software. 
•  Semi-preparative HPLC: Waters 2707 autosampler, Waters 2489 detector, Waters fraction collector III and software   
 ChromeScope. 
•  HPLC vials (300 µL polypropylene plastic, Waters) 
•  Nuclear Magnetic Resonance spectrometers (NMR): Varian Mercury 400 MHz or Bruker Avance III 600 MHz  
•  High-resolution mass spectrometer (HRMS): LTQ-FT Ultra (Thermo Scientific) 
•  Class-II microbiological safety cabinet (Biomat2) 
•  Synergy H1 hybrid spectrophotometer (Gen5 2.01 analysis software, Biotek). 
•  Cell incubator (Panasonic Incusafe)  
•  Inverse microscope (Olympus CK2) 
•  Cell culture flasks (TC Flask T25 stand, Vent. Cap, SARSTEDT, cat. no. 83.3910.002) 
•  Inoculation loop (10 µL, blue, sterile, Greiner bio-one, cat. no. 731171) 
•  Glass flat bottom flasks (250 mL, PYREX) 
•  Foam plug for flask (50 × 38 mm, King Scientific, cat. no. FS5038) 
•  8-well chamber (µ-Slide, ibiTreat, V2.0, sterilized, ibidi GmbH, cat. no. 80826) 
•  Miracloth (Merck Calbiochem, cat. no. 475855) 
•  Sterile disposable Petri dishes (9 cm, Thermo Scientific, cat. no.101IRR) 
•  Haemocytometer (Profondeur, 0.200 mm, 0.0625 mm2, Fuchs-Rosenthal, SUPERIOR MARIENFELD) 
•  Lens cleaning tissue (Whatman105, 100 × 150 mm, GE Healthcare, cat. no. 2105-841) 
•  Aluminum foil (45 cm, Terinex) 
•  3M Micropore surgical-tape (Micropore) 
•  TriStar LB941 multimode microplate reader (BertholdTech) 
•  Inverted confocal fluorescent microscope (Leica SP8) with temperature control unit (550W, the Cube E5CN-H) and environmental control box 
•  Autoclave (AL02-01, Advantage-Lab) 
•  Refrigerated incubator (Model MIR-153, 126 L, Sanyo) 
•  Shaking incubator (Innova 4400, New Brunswick) 
 
REAGENT SETUP 
        CRITICAL Autoclave all media on the same day they are prepared. 
! CAUTION Do not place materials that are not autoclave-safe in autoclave (non-heat resistant plastics and glass), as they will melt or 
shatter during sterilization cycle. Fill the container up to 2/3 of the maximum volume and always loosen up the lid of the bottles 
before autoclaving. 
Piperidine solution. Prepare a minimum of 110 mL of a piperidine: DMF (1:4) solution. This solution should be prepared fresh before 
use.  
! CAUTION Piperidine is toxic by inhalation. It must be handled with care inside a fume hood. 
Sample preparation for analytical HPLC and HPLC-MS. Dissolve an aliquot of the crude or the final products in a ACN: H2O (1:1) 
mixed solvent or in MeOH and then transfer into an HPLC vial. Aliquots containing other organic solvents must be first evaporated 
and redissolved in MeOH. Filter, when appropriate, through a 0.45 µm filter to remove any insoluble material. Typically, 5-50 µL 
volume injections are used for HPLC analysis.  
5 mM DMSO solutions of BODIPY-cPAF26 and PAF26 peptides. Dissolve 1.0 mg of each peptide in DMSO (152 μL for BODIPY-
cPAF26, 210 μL for PAF26) and store at -20 °C. In order to avoid several freeze-thaw cycles, DMSO stocks should be ideally stored in 
small multiple aliquots, which can be kept at -20 °C for at least 6 months without observing any degradation. 
! CAUTION DMSO is highly toxic. Gloves must be worn at all times to avoid contact with skin. 
1 μM fluorescein in 0.1 N NaOH in EtOH. Prepare a 10 mM solution of fluorescein in DMSO by weighing 3.3 mg and dissolving them 
in 1 mL of DMSO. Weigh 40 mg of NaOH in a 15 mL conical tube and dissolve in 10 mL EtOH. Dilute the 10 mM fluorescein solution in 
0.1 N NaOH in EtOH to a final concentration of 1 μM. This solution can be stored at r.t. in the dark for several days. 
! CAUTION NaOH is very corrosive; hence protective equipment (goggles, gloves, and lab coat) should be worn when handling this 
chemical. 
Citric acid/phosphate buffer (pH 7.0-7.1). Weigh 1 g of citric acid monohydrate in a 50 mL centrifuge tube and dissolve the solid in 
50 mL of sterile H2O. On a separate tube, weigh 2.7 g dibasic sodium phosphate heptahydrate and dissolve in 50 mL sterile H2O. Mix 
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21.9 mL of phosphate solution with 3.1 mL of citric acid solution and dilute to a total of 50 mL with sterile H2O. Check pH with the 
help of a pH meter (pH = 7.0-7.1). This buffer solution can be stored at 4 ˚C for several months. 
Protease cocktail. Weigh 1.5 mg protease type XIV in a 1.5 mL microcentrifuge tube and dissolve in 1.5 mL citric acid/phosphate 
buffer (pH 7.1) to obtain a 1 mg mL-1 stock solution. Dilute the stock solution in the same buffer to a final concentration of 1 μg mL-1. 
The protease cocktail should be prepared fresh before use. 
Cell culture medium. Mix 500 mL RPMI cell media 1640, 50 mL FBS, 5 mL Pen Strep and 5 mL L-Glu in a sterile environment. The 
resulting medium can be filtered using disposable bottle top filters with PES membranes and stored at 4 °C for 2–3 months. 
      CRITICAL Cell culture experiments must be performed in sterile conditions inside a class-II microbiological safety cabinet. 
Vogel’s sucrose minimal medium. Prepare solid Vogel’s sucrose minimal agar medium according to Tables 1-3, adding 2% (w/v) agar 
before autoclaving. To prepare liquid Vogel’s sucrose minimal medium, follow the same recipe excluding agar addition (autoclave 
and store at r.t.). This medium can be safely stored under sterile conditions at 4 oC for up to 12 months. 
SAB dextrose liquid medium. Dissolve 30 g of SAB liquid medium in 1 L dH2O (autoclave and store at r.t.). This medium can be safely 
stored under sterile conditions at 4 oC for up to 12 months. 
SAB dextrose agar medium. Dissolve 65 g of SAB agar in 1 L dH2O (autoclave and store at r.t.). This medium can be safely stored 
under sterile conditions at 4 oC for up to 12 months. 
PDA medium. Dissolve 40 g of PDA agar in 1 L dH2O (autoclave and store at r.t.). This medium can be safely stored under sterile 
conditions at 4 oC for up to 12 months. 
PDB medium. Dissolve 26.5 g of PDB medium in 1 L dH2O. Mix well and dissolve by heating with frequent agitation until complete 
dissolution. Boil for 1 min if needed (autoclave and store at r.t.). This medium can be safely stored under sterile conditions at 4 oC for 
up to 12 months. 
 
Table 1. 
 
Table 2. 
 
Table 3. 
 
Preparation of agar flasks for culturing fungal cells. Heat up and melt sterile  agar medium using a conventional microwave oven 
and pour 10 – 15 mL of it into sterile T25 cell culture flasks. Tighten the lids, lay the flasks down and let the agar cool down at r.t. 
Store the flasks at 4 oC in a sealed plastic bag for up to 6 months. 
Preparation of stock suspension aliquots of A. fumigatus. Streak A. fumigatus spores (purchased from FGSC) using a sterile 
inoculation loop onto the surface of solid Vogel’s sucrose minimal agar medium within a T25 cell culture flask, and incubate the flask 
at 37 ˚C in the dark for 3 days. Add 1 mL of sterile dH2O to the flask, shake gently and transfer the suspension containing fungal 
spores (conidia) with a P1000 micropipette to a 2 mL microcentrifuge tube. Add 0.5 mL glycerol to the tube, shake gently and 
prepare stock suspension aliquots of 100 µL into sterile 1.5 mL microcentrifuge tubes. Seal the tubes with parafilm and store them at 
– 80 oC for up to 12 months. 
Preparation of stock suspension aliquots of C. neoformans. Streak C. neoformans (purchased from FGSC) using a sterile inoculation 
loop onto  15 mL SAB dextrose agar medium within a 9 cm Petri dish. Transfer a single colony with a sterile pipette tip into a sterile 
glass flat-bottom flask containing 10 mL of liquid SAB dextrose liquid medium. Plug the flask with a sterile foam plug, seal the flask 
with aluminum foil and incubate the flask on a shaking incubator at 37 oC (170 rpm) for 20 h. Filter the suspension from the flask 
through folded Miracloth (4 layers) into a polypropylene conical tube, centrifuge for 5 min at r.t. (4,000 rpm, 1,755 g) and remove 
the supernatant. Resuspend the pellet in 2 mL glycerol: dH2O (3:7) and prepare stock aliquots of 100 µL into 1.5 mL microcentrifuge 
tubes. Seal the microcentrifuge tubes with parafilm and store them at – 80 oC for up to 12 months. 
Preparation of stock suspension aliquots of F. oxysporum. Add F. oxysporum microconidia spores (purchased from FGSC) using a 
sterile inoculation loop into a sterile glass flat-bottom flask with 20 mL of PDB medium. Plug the flask with a sterile foam plug, seal 
the flask with aluminum foil and incubate the flask on a shaking incubator at 28 oC (170 rpm) for 5 days. Filter the suspension from 
the flask through folded Miracloth (4 layers) into a polypropylene conical tube. Centrifuge for 10 min at r.t. (4,000 rpm, 1,755 g), 
discard the supernatant and resuspend the pellet in 1.5 mL of sterile dH2O (these steps must be repeated twice). Add 0.5 mL glycerol 
into the tube, shake the suspension and prepare stock aliquots of 100 µL into 1.5 mL microcentrifuge tubes. Seal the microcentrifuge 
tubes with parafilm and store them at – 80 oC for up to 12 months. 
Preparation of stock suspension aliquots of C. albicans. Transfer  a single colony of C. albicans  (purchased from ATCC) using a 
sterile inoculation loop into a sterile glass flat-bottom flask with 15 mL of PDB medium. Plug the flask with a sterile foam plug, seal 
the flask with foil and incubate the flask on a shaking incubator at 30 oC (170 rpm) for 12 h. Filter the suspension from the flask 
through folded Miracloth (4 layers) into a polypropylene conical tube, centrifuge for 5 min at r.t. (4,000 rpm, 1,755 g) and remove 
the supernatant. Resuspend the pellet in 2 mL glycerol: dH2O (3:7) and prepare stock aliquots of 100 µL into 1.5 mL microcentrifuge 
tubes. Seal the microcentrifuge tubes with parafilm and store them at – 80 oC for up to 12 months. 
        CRITICAL All these preparations must be performed in sterile conditions inside a class-II microbiological safety cabinet. 
 
EQUIPMENT SETUP 
Manual peptide-synthesis manifold. Place a vacuum manifold in the fume hood and connect it to the vacuum line including a trap. 
Use polystyrene syringe cartridges with polyethylene porous discs to retain the resins, and hold them on the manifold with two-way 
stopcocks. Cap all unused inlets with plastic septa. Use a Teflon stick for manual stirring. 
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Thermoblock shaker. Before incubating samples for protease degradation assays, the thermoblock shaker must be equilibrated at 37 
˚C. Once equilibrated, microcentrifuge tubes containing samples are covered in aluminum foil and shaken at 37 ˚C for the indicated 
times. 
Spectrophotometer. Settings for fluorescence readings: monochromator-based, excitation: 450 nm, emission: 480-600 nm with 1 
nm resolution, gain: 90-100. Settings for absorbance readings: 420-550 nm with 1 nm resolution or single endpoint measurements. 
HPLC-based analysis and purification. See Tables 4-6. 
 
Table 4. 
 
Table 5. 
 
Table 6. 
 
Autoclave. Autoclave all samples at 121 o C for 18 min without any drying cycles. Autoclave any lab ware/equipment (pipette tips 
etc.) at 121 oC for 15 min with a 15 min drying cycle and fast exhaust.  
! CAUTION Do not place materials that are not autoclave safe in autoclave (non-heat resistant plastics and glass) as they will melt or 
shatter during sterilization cycle. Fill the container up to 2/3 of the maximum volume and always loosen up the lid of the bottles 
before autoclaving. 
 
Confocal microscopy. We used a Leica TCS SP8 laser scanning confocal microscope with a tunable white light laser (WLL, 450-750 
nm), photomultiplier tubes (PMT), hybrid GaAsP (HyD) detectors and a 63× water immersion objective (HC PL APO UVIS CS2, 1.4 
N.A.) for fluorescence live-cell imaging. For live-cell imaging of different fungal species (steps 199-206), we used one excitation 
wavelength (496 nm, laser intensity: 20%) from the WLL source (power level: 70%) and the emission was detected between 505 and 
550 nm. A transmitted light detector was used for brightfield image acquisition (gain 355, offset 0%). For time-lapse high resolution 
imaging (steps 207-219), we used two different excitation wavelengths (i.e. 496 nm (laser intensity: 25%) and 570 nm (laser intensity: 
10 %) from the WLL (power level: 70%) and two emission bands (i.e. 505-550 nm (green) and 585-650 nm (red)). The transmitted 
light detector was used with the same settings as above. Images for time-lapse movies were acquired at 5 sec intervals. All images 
were acquired in a 1024 × 1024 pixel format and a scanning speed of 400 Hz. The pixel size of all images was 39.95 × 39.95 nm2.  
If live-cell images are taken with a different microscope, excitation should be performed within the 450-500 nm (green) and the 550-
600 nm ranges (red), and fluorescence emission should be collected using either band-pass or long-pass filters covering 500-550 nm 
(green) or 590-650 nm (red) ranges. Water and oil immersion objectives can be both used for image acquisition. The settings for 
image format and scanning speed should be adjusted depending on the requirements of the experiment. However, we recommend 
setting high pixel format and slow scanning speeds whenever possible.  
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PROCEDURE 
      CRITICAL  Cultures of the five different fungal species — N. crassa, A. fumigatus, C. neoformans, F. oxysporum, and 
C. albicans — (see steps 132–151) must be performed under sterile conditions using a class-II microbiological safety 
cabinet. All reagents and pipette tips must be sterile. Cultures of the various fungal species can be performed in parallel 
to maximize time efficiency. 
      CRITICAL Preparation of fungal cells for fluorescent live-cell imaging (see steps 163–189) must be performed under 
sterile conditions using a class-II microbiological safety cabinet. All reagents and pipette tips must be sterile. 
Preparation of the multiple species can be performed in parallel to maximize time efficiency. 
 
Synthesis of 4,4-difluoro-8-(3-iodophenyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (m-iodophenyl-BODIPY 
(3)) ● TIMING 32 h 
      CRITICAL As a visual aid, in Figure 8 are reported photos of various stages of the present sub-section of the 
Procedure. 
1| Weigh 500 mg 3-iodobenzaldehyde (1.0 eq., 2.2 mmol) in a 250 mL round-bottom flask containing a magnetic stir 
bar (egg-shaped, 25 × 10 mm). 
2| Cap the flask with a rubber septum (Φ 30.7 mm), place it on a magnetic stirrer and add to the flask 50 mL of 
anhydrous DCM using a 60 mL syringe under N2 stream while stirring the contents of the flask (stirring mot.: 70 % of full 
power).  
3| Add to the flask 500 µL 2,4-dimethylpyrrole (2.2 eq., 4.7 mmol) with a 1 mL syringe under N2 stream and constant 
stirring.  
4| Add to the flask four drops (~15 µL) of TFA with a 1-mL syringe under N2 stream. The solution turns orange. 
! CAUTION We recommend using a glass needle when working with TFA to avoid any potential contamination due to 
degradation of plastic syringes. 
5| Stir the reaction mixture under N2 stream at r.t. for 30 min (stirring mot.: 70 % of full power).  
6| Suspend the N2 flow and stir the reaction mixture under N2 atmosphere at r.t. for 22 h (stirring mot.: 70 % of full 
power). The solution turns dark red. 
7| Monitor the consumption of 3-iodobenzaldehyde and the formation of a new product by sampling an aliquot from 
the reaction mixture and performing analysis by TLC (DCM: hexane (1: 1), Rf ≈ 0.4-0.5) or HPLC (Gradient_2, Table 4). 
8| Weigh 490 mg DDQ (1.0 eq., 2.2 mmol) in a 50 mL conical flask and add to it 30 mL of anhydrous DCM. 
9| Shake and sonicate the resulting yellow suspension until it is almost completely dissolved. 
10| Add dropwise (for ~ 10 min) the solution prepared in step 9 to the reaction mixture with a syringe under N2 stream 
(stirring mot.: 80 % of full power). 
11| Rinse the conical flask with 2 mL of anhydrous DCM and transfer the solution dropwise to the reaction mixture (for 
~ 5 min). 
12| Stir the reaction mixture under N2 for 5 min. 
13| Suspend the N2 flow and stir the reaction mixture under N2 atmosphere for 10 min. 
14| Add to the reaction mixture dropwise 4 mL of TEA (45.0 eq., 97.0 mmol) with a syringe and under N2 stream. The 
solution turns dark green. 
15| Add to the reaction mixture dropwise (for ~ 3 min) 4 mL BF3·OEt2 (30.0 equivalents, 64.7 mmol) with a syringe and 
under a N2 stream. 
16| Stir the reaction mixture under a N2 stream for 3 min; then, suspend the N2 flow and stir the reaction mixture 
under N2 atmosphere for 4 h 30 min. 
17| Monitor the formation of the new product by sampling the reaction mixture and performing analysis by TLC (DCM: 
hexane (1: 1), Rf ~ 0.2-0.3) or HPLC (tR = 8.0 min; Gradient_2, Table 4). 
18| Remove the septum and transfer the reaction mixture into a 250 mL separatory funnel containing 50 mL of dH2O. 
Rinse the reaction flask with 20 mL of DCM. 
19| Place a stopper on the separatory funnel and shake vigorously 10 times. Remove the stopper, transfer the organic 
layer into a 250 mL conical flask and discard the aqueous layer into another 250 mL container. Transfer the organic 
layer back to the separatory funnel and repeat the step after adding another 50 mL of dH2O.  
20| Combine the aqueous layers and back-extract the resulting solution with 20 mL of DCM. Combine the organic 
layers, transfer them into a 250 mL conical flask and add to it the necessary amount of anhydrous Na2SO4.  
21| Filter the DCM solution into a 250 mL round-bottom flask through a funnel containing a small piece of glass wool at 
the bottom. Rinse the reaction flask with 20 mL DCM and add the resulting solution to the filtrate. 
22| Remove the organic solvent under reduced pressure (water bath max. T: 40 °C) using a rotary evaporator. 
 PAUSE POINT For storage, cap the flask and store the crude mixture at 4 °C. The crude mixture can be safely stored 
for at least 24 h.  
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23| Purify compound 3 (DCM: hexane (1: 1), Rf ~ 0.2) by flash column chromatography (Silica RediSep Rf 40 g flash 
column CV 53.9 mL - 40 mL/min), using a DCM: hexane linear gradient (increment rate: 1% DCM min-1) and dual-
wavelength detection (254 and 360 nm). When a compound is detected, change to isocratic mode until the compound 
is completely eluted. For loading, dissolve the crude mixture in 10 mL of DCM in a round-bottom flask and add to it two 
spatula tips of silica. Subsequently, remove the solvent under reduced pressure (water bath max. T: 30 °C) using a 
rotary evaporator. Transfer the silica-adsorbed crude mixture into a 60 mL polystyrene syringe cartridge and load into a 
CombiFlash purification system. Run the flash column chromatography with DCM: hexane at 40 mL min-1 and collect 12 
mL fractions. Typically, compound 3 elutes when the DCM: hexane volume ratio is 88: 12. The compound 3 might 
crystallize in some of the collection tubes. 
?  TROUBLESHOOTING 
24| Identify the fractions containing compound 3 by sampling aliquots from the collected tubes and analyzing them by 
HPLC (tR = 8.0 min; Gradient_2, Table 4). 
25| Combine the pure fractions into a 100 mL round-bottom flask and remove the solvent under reduced pressure 
(water bath max. T: 40 °C) using a rotary evaporator to obtain a red solid. The solid can be analyzed by HPLC-MS to 
check the purity and exact mass (tR: 4.5 min; HPLC-MS (2), Table 5).  
?  TROUBLESHOOTING 
 PAUSE POINT For storage, cap the flask and store compound 3 under N2 at 4 °C. Compound 3 can be safely stored for 
at least 9 months. 
 
Figure 8. 
 
Synthesis of Fmoc-Trp(C2-BODIPY)-OH (1) ● TIMING 5 h 
        CRITICAL As a visual aid, in Figure 9 are reported photos of various stages of the present sub-section of the 
Procedure. 
26| Weigh 3.3 mg Pd(OAc)2 (0.05 eq., 0.02 mmol), 57.1 mg AgBF4 (1.0 eq., 0.29 mmol) and 125 mg Fmoc-Trp-OH (1.0 
eq., 0.29 mmol) and transfer them as solids into a 10 mL microwave reaction vessel.  
27| Add to the microwave reaction vessel a magnetic stir bar (cylindrical stirring bar 10 × 3 mm). 
28| Place 198 mg of compound 3 (1.5 eq., 0.44 mmol) in a 5 mL round-bottom flask and transfer the compound to the 
microwave reaction vessel with anhydrous DMF (1.2 mL in 100 µL portions) using a micropipette. Shake the resulting 
solution. 
29| Add to the microwave reaction vessel 22 µL (0.29 mmol) of TFA using a micropipette and close the reaction vessel 
with a microwave cap. 
! CAUTION Due to the volatility and corrosiveness of TFA, we recommend using a glass syringe or pipette. 
30| Sonicate the solution for 10 seconds. 
31| Place the reaction mixture under microwave irradiation (250 W) at 80 °C for 20 min in a CEM Discover microwave 
synthesizer. Monitor the formation of compound 1 by sampling an aliquot from the crude mixture and performing 
analysis by HPLC (tR = 7.0 min; Gradient_2, Table 4). 
?  TROUBLESHOOTING 
32| Pack a pad of Celite into a fritted glass funnel and wash it twice with 25 mL EtOAc. 
33| Load the crude reaction mixture with a glass pipette. 
34| Rinse the reaction vessel with 25 mL of EtOAc and add the resulting solution to a flask fitted with a filter. Filter the 
solution containing the reaction mixture through Celite using vacuum and collect the filtrates in a 100 mL round-bottom 
flask. Wash the Celite pad twice with 17 mL of EtOAc each time. Evaporate the solvent under reduced pressure at 43 °C 
using a rotary evaporator (add portions of toluene to enhance DMF removal).  
 PAUSE POINT For storage, cap the flask and store the crude mixture at 4 °C The crude mixture can be safely stored 
for at least 24 h. 
35| Purify compound 1 (EtOAc, Rf ~ 0.3) by flash column chromatography (Silica RediSep Rf 12 g flash column CV 16.8 
mL - 30 mL min-1) using a EtOAC: hexane linear gradient (increment rate: 2% EtOAc min-1) and dual-wavelength 
detection (254 and 306 nm). When a compound is detected, change to isocratic mode until the compound is 
completely eluted. For loading, dissolve the crude mixture in 15 mL of EtOAc in a round-bottom flask and add to the 
resulting solution two spatula tips of silica. Subsequently, remove the solvent under reduced pressure (water bath max. 
T: 40 °C) using a rotary evaporator. Transfer the silica-adsorbed crude mixture into a 60 mL polystyrene syringe 
cartridge and load into a CombiFlash purification system. Run the flash column chromatography with EtOAc: hexane at 
30 mL min-1 and collect 12 mL fractions. Typically, compound 1 elutes when the EtOAc: hexane volume ratio is 3: 7. 
When 40 g columns are used, the product elutes when the EtOAc: hexane volume ratio is 1: 1. Compound 1 is isolated 
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as a red amorphous solid. The solid can be analyzed by HPLC-MS to check the purity and exact mass (tR: 9.6 min; HPLC-
MS (1), Table 5).  
 PAUSE POINT Compound 1 can be safely stored for at least 4 months at 4 °C under N2.  
 
Figure 9. 
 
Analysis of samples of the amino acid 1 stored for up to 4 months ● TIMING 1 h 
36| If compound 1, as obtained after completing step 35 above, is not used immediately after purification and is stored 
instead, its chemical purity needs to be reconfirmed before use. To test the compound stability as a solid, weigh 5 mg 
of the amino acid 1 in a 2 mL glass vial and wrap in aluminum foil. To test the compound stability in solution, weigh 2.2 
mg of the amino acid 1 in a 50 mL centrifuge tube and dissolve it in 30 mL of DCM, MeOH, or DMF to obtain 0.1 M 
solution. Aliquot the solution into three separate 15 mL conical tubes (10 mL each) and wrap them in aluminum foil.  
37| Store the three solution and one solid samples at three different temperatures: r.t., 4 ˚C, and -20 ˚C. At the 
indicated time points (i.e. 1 month, 2 month and 4 months), sample aliquots (spatula tip for solid, 50 μL for solutions), 
dilute in MeOH (50 μL) and analyze by HPLC-MS (tR: 9.6 min; HPLC-MS (1), Table 5). 
?  TROUBLESHOOTING 
 
Solid-phase peptide synthesis of BODIPY-cPAF26 ● TIMING 36 h  
      CRITICAL As a visual aid, in Figure 10 are reported photos of various stages of the present sub-section of the 
Procedure. 
38| Weigh 46 mg of 2-CTC-PS resin (loading capacity: 1.6 mmol g-1) into a 6 mL polystyrene syringe with a polyethylene 
porous disc. Place it in the vacuum manifold using a two-way stopcock. 
39| Swell the resin with DCM with gentle agitation using a Teflon stick (2 × 4 mL × 15 s). 
40| Calculate the amount of the first amino acid (Fmoc-Gly-OH) to achieve a loading capacity around 1 mmol g-1 (i.e. 
mass of resin (g) × 1 mmol g-1 × amino acid molecular weight (g mol-1), see Table 7).  
41| Weigh 14 mg of Fmoc-Gly-OH in a 1.5 mL microcentrifuge tube. Add to the tube 0.5 mL of DCM and 24 µL of DIPEA. 
Shake for a few seconds until the solid dissolves completely and add the solution to the syringe followed by manual 
stirring using a Teflon stick. Wash the microcentrifuge tube with 0.5 mL DCM and add the washing liquid to the syringe 
followed by manual stirring using a Teflon stick. 
42| Shake the syringe in an orbital shaker for 10 min at 200 rpm (4 g). 
43| Add to the syringe 55 µL of DIPEA without filtering and shake the syringe in an orbital shaker for 40 min at 200 rpm 
(4 g).  
44| Add 36 µL of MeOH (0.8 µL MeOH per mg resin) to the resin without filtering to cap unreacted groups. Shake the 
syringe in an orbital shaker for 10 min at 200 rpm (4 g). 
45| Put the syringe in the vacuum manifold and drain the resin.  
46| Wash the resin thoroughly with DCM (4 × 3 mL × 10 s) and DMF (4 × 3 mL × 10 s), and apply vacuum to drain the 
resin after each wash. 
47| Add to the syringe a piperidine: DMF (1: 4) solution to remove the Fmoc protecting group (1 × 5 mL × 1 min + 2 × 5 
mL × 5 min). For each wash, gently shake the reaction mixture with the Teflon stick and then drain the resin under 
vacuum.  
48| Calculate the amount of the second amino acid and the coupling reagents (Fmoc-Trp-OH, DIC and OxymaPure) 
needed on the basis of the amount of resin and functionalization (i.e. mass of resin (g) × 1 mmol g-1 × 3 eq. × reagent 
molecular weight (g mol-1) see Table 7). 
49| Weigh the amino acid and OxymaPure as calculated in step 48 in a 1.5 mL microcentrifuge tube. 
50| Wash the resin thoroughly with DCM (4 × 3 mL × 10 s) and DMF (4 × 3 mL × 10 s), and apply vacuum to drain the 
resin after each wash. 
51| Dissolve the reagents from step 49 in 0.5 mL of DMF, add 21 µL of DIC, and shake the resulting solution for 5 min. 
52| Add the resulting activated amino acid solution to the resin and gently shake the resulting reaction mixture with 
the Teflon stick for 4 min. 
53| Shake the syringe in an orbital shaker for 56 min at 200 rpm (4 g) and then drain the resin. Wash the resin as in step 
50. 
54| Run a Kaiser test53 to assess the extent of the peptide coupling. 
?  TROUBLESHOOTING 
55| Repeat steps 48–54 for coupling all following amino acid (i.e. Fmoc-Phe-OH) and steps 46–47 for Fmoc removal. 
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 PAUSE POINT Peptide elongation can be paused at any point after the incorporation of the third amino acid.  Pausing 
after the incorporation of the second amino acid is not recommended due to the potential formation of 
diketopiperazines.54 Storing the peptide as Fmoc-protected is not recommended, because partial Fmoc removal can 
lead to re-incorporation of the fluorenylmethyl moiety to the free amine group giving the corresponding secondary 
amine.  For storage, wash the resin 3 times with DCM or DMF (5 mL each), wrap the syringe in aluminium foil and store 
at r.t. The resin can be safely stored at 4 °C for at least 24 h. 
 
56| For the coupling of the amino acid 1, calculate the amount of amino acid and coupling reagents (1, HOBt, PyBOP 
and DIPEA) needed on the basis of the amount of resin and functionalization (i.e. mass of resin (g) × 1 mmol g-1 × 1.5 or 
2 eq. × reagent molecular weight (g mol-1), see Table 7). 
57| Weigh the amino acid and HOBt as calculated in step 56 in a 1.5 mL microcentrifuge tube. Separately, weigh PyBOP 
in a separate 1.5 mL microcentrifuge tube. 
58| Wash the resin thoroughly with DCM (4 × 3 mL × 10 s) and DMF (4 × 3 mL × 10 s), and apply vacuum to drain the 
resin after each wash.  
59| Dissolve PyBOP from step 57 in 0.1 mL of DMF. 
60| Dissolve the reagents from step 57 in 0.4 mL of DMF. Add to the resulting solution 16 µL DIPEA (2 eq.) and the 
PyBOP solution from step 59. Shake the resulting solution for 2 s, add it to the resin and gently shake the resulting 
reaction mixture with the Teflon stick for 4 min. 
61| Shake the syringe in an orbital shaker for 56 min at 200 rpm (4 g) and then drain the resin. Wash the resin as in step 
58. 
62| Run a Kaiser test53 to assess the extent of the coupling. 
?  TROUBLESHOOTING 
 PAUSE POINT For storage, wash and drain the resin three times with DCM (5 mL of DCM per wash-drain cycle), wrap 
the syringe in aluminum foil and store the resin at r.t. for 24 h.  
 
Table 7. 
 
63| Wash the resin thoroughly with DCM (4 × 3 mL × 10 s) and DMF (4 × 3 mL × 10 s), and apply vacuum to drain the 
resin after each wash. 
! CAUTION Always use a Teflon two-way stopcock when working with TFA (see next step). 
64| Add 3 mL of a freshly prepared TFA: DCM (1: 99) solution to the resin. Shake gently with a Teflon stick for 1 min. 
Collect the filtrates in a 100 mL round-bottom flask with 30 mL DCM. Keep constant stirring of the solution in a 
magnetic stirrer (egg-shaped stirring bar 2 cm × 1 cm, stirring mot.: 60% of full power). Wash the resin with DCM (3 mL 
× 5 s) and collect the filtrates in the same flask. 
65| Repeat step 64 another four times with an additional final wash with DCM (3 mL × 5 s), collecting all the filtrates in 
the same flask. 
66| Remove the solvent under reduced pressure (water bath max. T: 40 °C) using a rotary evaporator. 
 CRITICAL Low acidic conditions and short reaction times are critical to preserve the integrity of the BODIPY 
fluorophore. 
67| Dissolve the crude reaction mixture obtained in step 66 in 14 mL of ACN: H2O (1:1), adding first ACN and then H2O 
in a 50 mL polypropylene centrifuge tube.  
 CRITICAL The ACN volume should be reduced to the minimum in order to avoid melting the crude peptide solution 
during freeze-drying.  
68| Freeze the crude peptide solution using liquid N2. Lyophilize for 24 h, wrapping the glass container in aluminum foil. 
69| Sample a small aliquot of the peptide crude, dissolve in ACN: H2O (1: 1) and analyze by HPLC-MS to check the crude 
purity and the exact mass (tR: 3.1 min; HPLC-MS (2), Table 5). 
 
Figure 10. 
 
Cyclization of the protected peptide ● TIMING 3 h 
70| Weigh 14 mg of HATU (1.0 eq., 0.04 mmol) in the 50 mL centrifuge tube from step 68, which should contain 61 mg 
of linear protected peptide (0.04 mmol). The amount of HATU should be stoichiometrically determined according to the 
amount of peptide obtained.  
71| Dissolve the compounds in 0.9 mL anhydrous DMF and add 16 µL DIPEA (2.5 eq., 0.09 mmol). 
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72| Stir the solution for 2 h at r.t. on a magnetic stirrer (cylindrical stirring bar 8 × 3 mm, stirring mot.: 80% of full 
power). Sample a small aliquot of the peptide crude, dissolve in ACN: H2O (1: 1) and analyze by HPLC-MS to confirm the 
reaction is completed (tR: 4.1 min; HPLC-MS (2), Table 5). 
73| Add to the 50 ml centrifuge tube dropwise 12 mL of cold (5-10 ºC) H2O to precipitate the protected peptide. 
74| Vortex the mixture for 1 min, centrifuge for 5 min at 4,000 rpm (1,610 g) and carefully decant H2O. 
75| Repeat steps 73-74 two additional times. 
 
Lyophilization of the cyclic protected peptide ● TIMING 24 h 
76| Re-dissolve the protected peptide in 8 mL of ACN: H2O (1: 1). Freeze the crude peptide solution using liquid N2. 
Lyophilize for 24 h, wrapping the glass container in aluminum foil. 
77| Sample a small aliquot of the peptide crude, dissolve in ACN: H2O (1: 1) and analyze by HPLC to check the purity (tR: 
4.1 min; HPLC-MS (2), Table 5). 
 PAUSE POINT For storage, wrap the centrifuge tube in aluminum foil and store at 4 °C. The peptide can be safely 
stored at 4 °C for at least 7 days. 
 
Hydrogenation reaction ● TIMING 49 h 
      CRITICAL As a visual aid, in Figure 11 are reported photos of various stages of the present sub-section of the 
Procedure. 
78| Weigh 45 mg of protected BODIPY-cPAF26 peptide from step 76 (1.0 eq., 0.03 mmol) and 23 mg of Pd(OH)2-C in a 
25 mL round-bottom flask containing a magnetic stir bar (cylindrical stirring bar 10 × 3 mm). 
79| Cap the flask with a rubber septum (Φ 14.9 mm). Evacuate and backfill the flask with Ar or N2.  
80| Add 4.5 mL of freshly prepared MeOH: formic acid (95: 5) with a syringe and purge for 5 min. 
81| Connect a balloon filled with hydrogen (H2) to the system through a needle and purge the flask with H2.  
82| Stir the reaction mixture under H2 atmosphere on a magnetic stirrer at r.t. for 48 h (stirring mot.: 80% of full 
power). Refill the H2 balloon periodically along with re-addition of Pd(OH)2-C (3 times overall). Sample a small aliquot of 
the peptide crude, dissolve it in 0.5 mL ACN: H2O (1: 1) and analyze by HPLC-MS to confirm that the reaction is 
completed (tR: 5.4 min for BODIPY-cPAF26; HPLC-MS (1), Table 5). 
! CAUTION H2 is a highly flammable gas. H2 gas must be always handled inside a ventilated fume hood.   
! CAUTION Once the reaction is complete and before the work-up, the H2 atmosphere should be replaced by N2 or Ar 
before filtering in order to avoid ignition of the charcoal. 
?  TROUBLESHOOTING 
83| Filter the solution through a glass Pasteur pipette containing Celite and a tiny piece of cotton at the bottom. Wash 
the filter with 3 mL MeOH to ensure complete elution of the peptide. 
84| Remove the solvent under reduced pressure (water bath max. T: 40 °C) using a rotary evaporator. 
 
 
Purification of BODIPY-cPAF26 ● TIMING 51 h 
85| Dissolve 25 mg of the crude BODIPY-cPAF26 peptide from step 84 in 1.5 mL ACN: H2O (1: 1). Heating for a few 
minutes in a water bath at 40 °C or sonicating help to dissolve the sample. 
86| Filter the solution through a 0.45 µm syringe filter into a 3 mL vial for semi-preparative HPLC purification (see Table 
6). Rinse the round-bottom flask with 0.5 mL ACN: H2O (1: 1), filter and transfer to the same vial. 
87| Inject 500 µL of the solution just prepared to the semi-preparative HPLC. BODIPY-cPAF26 elutes around tR: 12-14 
min (ACN: H2O (4:6)). Collect the pure BODIPY-cPAF26 peptide in a 50 mL centrifuge tube (~ 30 mL per injection). 
88| Repeat step 87 three more times. 
89| Combine all the pure fractions. Freeze them using liquid N2 and lyophilize for 48 h, wrapping the glass container in 
aluminum foil. Sample a small aliquot of the peptide, dissolve in ACN: H2O (1: 1) and analyze by HPLC-MS to confirm the 
purity of the peptide (tR: 5.4 min for BODIPY-cPAF26; HPLC-MS (1), Table 5). 
 PAUSE POINT For storage, wrap the centrifuge tubes in aluminum foil and store them at 4 °C under N2 atmosphere. 
The peptide can be safely stored at 4 °C for at least 6 months.  
 
Figure 11. 
 
Proteolytic stability of BODIPY-cPAF26 and PAF26 peptides ● TIMING 25 h   
90| Aliquot 20 μL of 5 mM DMSO solutions of BODIPY-cPAF26 and PAF26 peptides into two separate 1.5 mL 
microcentrifuge tubes. 
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91| Dilute both peptides in 480 μL of protease cocktail (1 μg mL-1, pH 7.1) to reach 200 μM final concentration. 
92| Vortex the two solutions. Aliquot samples (62 μL) for the first time point (t = 0), precipitate the proteins by 
microcentrifugation (4 ˚C, 13,000 rpm, 18,530 g), and analyze the supernatants by HPLC-MS (tR: 4.2 min for PAF26, 5.4 
min for BODIPY-cPAF26; HPLC-MS (1), Table 5). 
93| Place the solutions in the pre-heated thermoblock shaker at 37 ˚C (see Equipment setup). Shake the tubes at 950 
rpm and take aliquots (62 μL) at the indicated time points (i.e. 0.25 h, 1 h, 4 h, 8 h, and 24 h).  
94| Precipitate the proteins by microcentrifugation (4 ˚C, 13,000 rpm, 18,530 g), and analyze the supernatants by HPLC-
MS (tR: 5.4 min for BODIPY-cPAF26; HPLC-MS (1), Table 5). 
?  TROUBLESHOOTING 
 
Test of BODIPY-cPAF26 fluorogenic behavior of in phospholipid membranes ● TIMING 1.5 h   
95| Dilute 40 μL of the 5 mM DMSO solution of BODIPY-cPAF26 with 40 μL of DMSO to reach 2.5 mM final 
concentration. 
96| Vortex the phosphatidylcholine (PC): cholesterol (7: 1) liposome suspension in PBS (7.5 mg mL-1 PC) for 10 seconds. 
      CRITICAL Liposome suspensions must be used at r.t. and stored at 4 ˚C, but cannot be frozen. 
97| Dilute the 7.5 mg mL-1 PC liposome suspension in 2-fold serial dilutions (495 μL in 1.5 mL microcentrifuge tubes) 
using DPBS. Prepare 10 serial dilutions, ranging from 3.75 mg mL-1 PC (2-fold dilution) to 0.007 mg mL-1 PC (1024-fold 
dilution). Prepare a blank sample with only DPBS (495 μL in a 1.5 mL microcentrifuge tube). 
98| Add 5 μL of 2.5 mM BODIPY-cPAF26 solution to all liposome suspensions and also to the DPBS blank to reach 25 
μM final concentrations. 
99| Vortex all the liposome suspensions and the DPBS blank for 10 seconds. 
100| Transfer 150 μL (× 3) from every suspension onto separate wells of a 96-well black plate with flat bottom and lid. 
Include 3 wells (150 μL each) of 1 μM fluorescein in 0.1 N basic EtOH as a reference for the quantum yield 
measurements. 
101| Incubate the plate for 15 min at r.t. in the dark.  
      CRITICAL Do not incubate BODIPY-cPAF26 with liposomes for longer than 30 min as sedimentation of the peptide 
can lead to inaccurate measurements. 
102| Measure fluorescence emission spectra for the 96-well black plate using a Synergy H1 spectrophotometer. 
Excitation wavelength: 450 nm, emission range: 480-600 nm (every 1 nm). 
103| Transfer samples to a 96-well polystyrene transparent plate using a multichannel pipette. As a reference for 
background measurements, make sure to fill three wells with 150 μL of DPBS each. 
104| Measure absorbance spectra of the 96-well transparent plate using a Synergy H1 spectrophotometer. Absorbance 
range: 420-550 nm (every 1 nm).  
105| Transfer BODIPY-cPAF26 suspensions with high liposome content, low liposome content, DPBS blank as well as 
fluorescein in basic EtOH into 2 mL glass vials. 
106| Irradiate the glass vials with 365 nm light using a hand-held UV-lamp. Differences in fluorescence intensity of 
BODIPY-cPAF26 can be detected by naked eye (see Figure 12). 
! CAUTION Exposure to UV radiation can cause skin or eye burns; hence protective equipment (goggles, gloves and lab 
coat) should be worn. 
?  TROUBLESHOOTING 
 
Figure 12. 
 
Testing BODIPY-cPAF26 cytotoxicity in A549 human lung epithelial cells ● TIMING 42 h   
      CRITICAL Cell culture experiments must be performed in sterile conditions using a class-II microbiological safety 
cabinet. All reagents (media, DPBS, Trypsin-EDTA) and pipette tips must be sterile. 
107| Use a running culture of A549 cells, typically one T-75 cell culture flask with 25 mL cell culture medium (see 
Reagent setup) incubated at 37 ˚C in 5% CO2. 
108| Check confluency and morphology of the cells under a microscope. 
      CRITICAL Live A549 cells should be adhering to the flask. If most cells are floating or show signs of contamination 
(e.g. presence of bacteria or a cloudy medium), discard the culture and use a new batch.   
109| Remove and discard the medium with a 25 mL plastic pipette. 
110| Gently add 10 mL of Ca2+-free DPBS to wash the cells then remove and discard the washing liquid with a 10 mL 
plastic pipette. 
111| Add 1 mL of Trypsin-EDTA to the flask, rock gently to cover the entire surface of the flask and incubate for 3 min at 
37 ˚C in 5% CO2. 
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?  TROUBLESHOOTING 
112| Take the flask out of the incubator, tap gently to detach cells, add 10 mL of cell culture medium to the flask and 
transfer the cell suspension to a 50 mL centrifuge tube. 
113| Collect a 50 μL aliquot of the cell suspension for cell counting. 
114| Determine the number of cells using a cell counter. In one fully confluent flask of A549 cells, counts are typically ~ 
0.5–2 × 106 cells mL-1, depending on their manipulation.  
115| Centrifuge the cell suspension (5 min, 20 ˚C, 350 rpm, 189 g). 
116| Discard the supernatant and resuspend the cell pellet in 1 mL of cell culture medium. Calculate the amount of 
cells needed for the cytotoxicity assay depending on the wells to be used (25,000 cells/well). In a standard assay with 
six different conditions and four replicates (total of 24 wells), around 6 × 105 cells are needed. 
117| Dilute the cell suspension in  cell culture medium to achieve a final concentration of 2.5 × 105 cells mL-1, and place 
the cell suspension in a 50 mL pipette basin.  
118| Plate cells (100 μL/well) in sterile 96-well flat bottom polystyrene clear plates with lid using a multichannel 
pipette. Discard leftover cells following biological waste disposal regulations. 
119| Incubate the plate(s) for 16 h at 37 ˚C in 5% CO2. 
120| Check confluency and morphology of the cells under a microscope. 
?  TROUBLESHOOTING 
121| Transfer 4 μL of a 5 mM BODIPY-cPAF26 solution to a 1.5 mL microcentrifuge tube and dilute the solution to 1 
mM final concentration adding to it 16 μL of DMSO. 
122| Prepare three more dilutions from 1 mM BODIPY-cPAF26 in DMSO (2-fold serial dilutions) in separate 1.5 mL 
microcentrifuge tubes to obtain 0.5 mM, 0.25 mM and 0.125 mM DMSO solutions. 
123| Dilute the four DMSO solutions in cell culture medium (9 μL of DMSO solutions plus 90 μL medium) to obtain 90 
μM, 45 μM, 22.5 μM, and 11.25 μM solutions of BODIPY-cPAF26. Prepare an additional blank solution with 9 μL of 
DPBS plus 90 μL of cell culture medium.   
124| Add 12.4 μL of the solutions to the cells in the 96-well plate to reach a final concentration of BODIPY-cPAF26 of 10 
μM, 5 μM, 2.5 μM, and 1.25 μM. As negative controls, add 12.4 μL of DPBS solution, and as positive controls, remove 
medium from the wells and add 112 μL DMSO to the cells. 
125| Rock the plate(s) gently and incubate the cells for 4 h at 37 ˚C in 5% CO2. 
126| Dilute an appropriate volume of MTT reagent with cell culture medium (2.3-fold dilution, a minimum of 30 μL 
solution/well is required), and place the solution in a 50 mL pipette basin.  
127| Add 30 μL of the MTT solution in cell culture medium just prepared to each well using a multichannel pipette. 
128| Rock the plate(s) gently and incubate the cells for 4 h at 37 ˚C in 5% CO2. 
      CRITICAL Under the microscope, check the progression of the MTT reaction by observing the precipitation of a dark 
solid within the cells.  
?  TROUBLESHOOTING 
129| Place enough detergent reagent in a 50 mL pipette basin (a minimum of 100 μL detergent/well is required). 
130| Add 100 μL detergent to each well using a multichannel pipette. Rock gently the plate, wrap it in aluminum foil 
and keep at r.t. for a minimum of 2 h. 
 PAUSE POINT At this point, the experiment can be paused and the plate can be kept at r.t. overnight.  
      CRITICAL Typically, 2-4 h incubation with detergent are enough to obtain the needed data, but overnight incubation 
is recommended to ensure full solubilization of the MTT reagent. 
131| Measure absorbance at 570 nm and 650 nm (background signal) of the 96-well transparent plate using a Synergy 
H1 spectrophotometer. Wells with high cell viability values (DPBS-containing negative control) are dark colored, 
whereas wells with low cell viability (full DMSO positive control) are yellow colored (see Figure 13). Absorbance values 
should be between 0.5 and 1.5 AU. 
?  TROUBLESHOOTING 
 
Figure 13. 
 
Culture of N. crassa ● TIMING 121 h 
132| Streak N. crassa spores from a stock culture (purchased from FGSC) using a sterile inoculation loop onto the 
surface of solid Vogel’s sucrose minimal agar medium (10-15 mL) within a T25 cell culture flask. 
133| Incubate the flask at 25 ˚C in the refrigerated incubator under 15 W ‘warm white’ light for 5 days. 
?  TROUBLESHOOTING 
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134| Add 1.5 mL of sterile dH2O to the flask, shake gently and recover the suspension containing fungal cells with a 
P1000 micropipette. Filter the suspension through folded Miracloth (4 layers) into a sterile 1.5 mL microcentrifuge 
tube. 
135| Remove a 4-µL aliquot of the cell suspension and transfer it to a hemocytometer to count the spores. 
   PAUSE POINT The N. crassa conidial suspension in sterile dH2O can be stored for up to 4 days at 4 ˚C. 
        CRITICAL Past the 4-days storage mark, N. crassa conidia must be discarded following biological waste disposal 
regulations. All inoculations should be performed from original stock cultures and not from sub-cultures to reduce the 
possibility of cultures acquiring new mutations. 
 
Culture of A. fumigatus ● TIMING 73 h 
136| Thaw and vortex one stock suspension aliquot of A. fumigatus to produce a homogeneous cell suspension. 
137| Add 50 µL of the homogeneous cell suspension onto the surface of solid Vogel’s sucrose minimal agar medium 
within a T25 cell culture flasks and spread the conidia over the agar surface with a sterile inoculation loop. 
138| Incubate the flask at 37 ˚C in the dark for 3 days. 
?  TROUBLESHOOTING 
139| Prepare 0.05 % (v/v) Tween 80 solution in sterile dH2O and add 1.5 mL of it to the flask. Shake gently the resulting 
mixture and recover the suspension with a P1000 micropipette. 
140| Remove a 4 µL-aliquot of the cell suspension and transfer to a hemocytometer to count the spores. 
  PAUSE POINT A. fumigatus conidial suspension in sterile dH2O can be stored for up to one month at 4 ˚C. 
        CRITICAL Past the one-month storage mark, A. fumigatus conidia must be discarded following biological waste 
disposal regulations. All inoculations should be performed from original stock cultures and not from sub-cultures to 
reduce the possibility of cultures acquiring new mutations. 
 
Culture of C. neoformans ● TIMING 73 h 
141| Thaw and vortex one stock suspension aliquot of C. neoformans and gently streak onto 15 mL SAB dextrose agar 
medium within a 9 cm Petri dish. 
142| Seal the plate with Micropore tape, place it inverted in an incubator and keep it there at 30 ˚C for 3 days. 
?  TROUBLESHOOTING 
  PAUSE POINT Petri dishes containing C. neoformans colonies can be stored for up to one month at 4 ˚C. 
       CRITICAL Past the one-month storage mark, C. neoformans colonies must be discarded following biological waste 
disposal regulations. All inoculations should be performed from original stock cultures and not from sub-cultures to 
reduce the possibility of cultures acquiring new mutations. 
 
Culture of F. oxysporum ● TIMING 121 h 
143| Thaw and vortex one stock suspension aliquot of F. oxysporum to produce a homogeneous cell suspension. 
144| Add 50 µL of the homogeneous cell suspension to a sterile glass flat-bottom flask with 20 mL of PDB medium. 
145| Plug the flask with a sterile foam plug and seal the flask with aluminum foil. Incubate the flask on a shaking 
incubator at 28 ˚C for 5 days. 
?  TROUBLESHOOTING 
146| Filter the cell suspension through folded Miracloth (4 layers) and transfer it into a sterile 50 mL centrifuge tube. 
147| Centrifuge the suspension for 10 min at r.t. (4,000 rpm, 1,755 g) and discard the supernatant. 
148| Re-suspend the pellet in 2 mL of sterile dH2O and transfer the resulting suspension with a P1000 micropipette into 
a 2 mL microcentrifuge tube. 
149| Remove a 4 µL-aliquot of the cell suspension and transfer it to a hemocytometer to count the spores. 
  PAUSE POINT F. oxysporum conidia suspension in sterile dH2O can be stored for up to one month at 4 ˚C. 
        CRITICAL Past the one-month storage mark, F. oxysporum conidia must be discarded following biological waste 
disposal regulations. All inoculations should be performed from original stock cultures and not from sub-cultures to 
reduce the possibility of cultures acquiring new mutations. 
 
Culture of C. albicans ● TIMING 73 h 
150| Thaw and vortex one stock suspension aliquot of C. albicans and gently streak onto 15 mL PDA medium within a 9 
cm Petri dish. 
151| Seal the plate, place it inverted in an incubator, and keep it there at 30 ˚C for 3 days. 
?  TROUBLESHOOTING 
  PAUSE POINT Petri dishes containing C. albicans colonies can be stored for up to one month at 4 ˚C. 
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        CRITICAL Past the one-month storage mark, C. albicans colonies must be discarded following biological waste 
disposal regulations. All inoculations should be performed from original stock cultures and not from sub-cultures to 
reduce the possibility of cultures acquiring new mutations. 
 
Antifungal activity measurements of BODIPY-cPAF26 and PAF26 peptides in N. crassa and A. fumigatus ● TIMING 26 
h 
152| In a 1.5 mL microcentrifuge tube, dilute 20 μL of a 5 mM BODIPY-cPAF26 or PAF26 solution with 80 μL of DMSO to 
obtain a 1 mM solution. 
153| Prepare another two dilutions of the 1 mM BODIPY-cPAF26 or PAF26 solution in DMSO in separate 1.5 mL 
microcentrifuge tubes to obtain 30 μM (30 μL of 1 mM peptide and 970 μL dH2O) and 25 μM (25 μL of 1 mM peptide 
and 975 μL dH2O) solutions. 
154| Add 100 μL of the 30 μM peptide solution into each of the wells (A1-G1) of a transparent U-bottom 96-well plate 
(Figure 14a). 
155| Add 100 μL of the 25 μM peptide solution into each of the wells (A2-G2) of a transparent U-bottom 96-well plate 
(Figure 14a).  
156| Add 100 μL of sterile dH2O into each of wells D1, H1, D2, and H2, and 50 μL of sterile dH2O into each of the rest of 
the wells. 
157| Perform 2-fold serial dilutions of the 30 μM peptide solution prepared in step 153 using a multichannel electronic 
pipette by transferring 50 μL from column 1 into column 3 and then 5 and so on. Discard the 50 μL taken from column 
11 (Figure 14b).  
158| Perform 2-fold serial dilutions of the 25 μM peptide solution prepared in step 153 using a multichannel electronic 
pipette by transferring 50 μL from column 2 into column 4 and then 6 and so on. Discard the 50 μL taken from column 
10. (Figure 14c).  
159| Dilute the conidial suspension from step 134 (N. crassa) or step 139 (A. fumigatus) with 5 mL solution of liquid 
Vogel’s sucrose minimal medium in dH2O (1: 4) to reach a final concentration of 106 cells mL-1.  Vortex the suspension 
and place it in a 50 mL pipette basin.  
160| Add 50 μL of the conidial suspension just obtained into each well using a multichannel pipette to achieve a final 
volume of 100 μL/well and a concentration of 5 × 105 cells mL-1, excluding wells that will act as blanks in rows D and H. 
To the blank wells in rows D and H, add 50 μL of a solution of liquid Vogel’s sucrose minimal medium in dH2O (1: 4) to 
achieve a final volume of 100 μL/well (Figure 14d). 
      CRITICAL STEP The addition of the conidia to the wells of the 96-well plate must be performed quickly to avoid any 
of the conidia settling in the pipette basin.  
161| Put the lid on the plate and wrap it in aluminum foil. Incubate for 24 h at 37 ˚C in the case of A. fumigatus or at 
25˚C in the case of N. crassa. 
 
Figure 14. 
 
162| Measure the optical density of the contents of the plate at 610 nm using a spectrophotometer. Optical density 
values for the control group (conidia alone) should be ~ 0.1-0.2 AU. IC50 values are determined by four-parameter 
logistic regression analysis. 
?  TROUBLESHOOTING 
 
Preparation of N. crassa conidial germlings for live-cell fluorescence imaging ● TIMING 4.5 h  
163| Vortex the cell suspension of N. crassa conidia from step 134. 
164| Dilute N. crassa conidia to 105 cells mL-1 with a 2 mL solution of liquid Vogel’s sucrose minimal medium in dH2O (1: 
4). 
165| Vortex the diluted suspension and transfer it to an 8-well chamber (200 µL/well) with a P200 micropipette. 
166| Incubate the 8-well chamber in a refrigerated incubator for 4 h at 25 ˚C in the dark. 
      CRITICAL A dilution of liquid Vogel’s sucrose minimal medium in dH2O (1: 4) must be used instead of 100% liquid 
Vogel’s sucrose minimal medium to produce N. crassa as conidial germlings and avoid the formation of mature hyphae, 
which are not suitable for single-cell imaging. 
 
Preparation of A. fumigatus conidial germlings for live-cell fluorescence imaging● TIMING 25 h  
167| Vortex the cell suspension of A. fumigatus conidia from step 139. 
168| Dilute A. fumigatus conidia to 105 cells mL-1 with a 2 mL solution of liquid Vogel’s sucrose minimal medium in 
dH2O (1: 4). 
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169| Vortex the diluted suspension and transfer it to an 8-well chamber (200 µL/well) with a P200 micropipette. 
170| Incubate the 8-well chamber in a refrigerated incubator for 24 h at 25 ˚C in the dark. 
        CRITICAL A dilution of liquid Vogel’s sucrose minimal medium in dH2O (1: 4) must be used instead of 100% liquid 
Vogel’s sucrose minimal medium to produce A. fumigatus as conidial germlings and avoid the formation of mature 
hyphae, which are not suitable for single cell imaging. 
 
Preparation of C. neoformans cells for live-cell fluorescence imaging ● TIMING 21.5 h  
171| Transfer 3-4 colonies of C. neoformans from step 142 into a sterile glass flat-bottom flask containing 10 mL of 
liquid SAB medium. 
172| Plug the flask with a sterile foam plug and seal the flask with aluminum foil. Incubate the flask on a shaking 
incubator at 37 ˚C for 20 h (170 rpm). 
173| Filter the cell suspension through folded Miracloth (4 layers) then transfer it into a sterile 50 mL centrifuge tube. 
174| Centrifuge the suspension for 5 min at r.t. (4,000 rpm, 1,755 g)) and discard the supernatant. 
175| Re-suspend the pellet in 2 mL of sterile dH2O and transfer the resulting suspension to a 2 mL microcentrifuge 
tube. 
176| Remove a 4 µL-aliquot of the cell suspension and transfer it to a hemocytometer to count the spores. 
177| Dilute C. neoformans conidia to 5 × 105 cells mL-1 in sterile dH2O.  
178| Vortex the diluted suspension and transfer it to an 8-well chamber (200 µL/well) with a P200 micropipette. 
179| Incubate the 8-well chamber at 37 ˚C for 30 min. 
        CRITICAL The chamber containing C. neoformans cells must be handled carefully as they will not adhere to the 
bottom of the 8-well chamber as well as the other fungal species. 
?  TROUBLESHOOTING 
 
Preparation of F. oxysporum cells for live-cell fluorescence imaging ● TIMING 9 h  
180| Dilute F. oxysporum microconidial suspension from step 148 to 5 × 105 cells mL-1 with 2 mL of a solution of PDB 
medium: dH2O (1:99).  
181| Vortex the diluted cell suspension and transfer it to an 8-well chamber (200 µL/well) with a P200 micropipette. 
182| Incubate the 8-well chamber in a refrigerated incubator at 25 ˚C for 8 h.  
 
Preparation of C. albicans cells for live-cell fluorescence imaging ● TIMING 13.5 h 
183| Transfer one single colony of C. albicans from step 151 into a sterile glass flat-bottom flask containing 15 mL PDB 
medium. 
184| Plug the flask with a sterile foam plug and seal the flask with aluminum foil. Incubate the flask on a shaking 
incubator at 30 ˚C for 12 h (170 rpm). 
185| Filter the suspension through folded Miracloth (4 layers) and transfer the filtrate into a sterile 50 mL centrifuge 
tube. 
186| Remove a 4 µL-aliquot of the cell suspension and transfer it to a hemocytometer to count the yeast cells. 
187| Dilute the C. albicans cells to 5 × 105 cells mL-1 in PDB medium.  
188| Vortex the diluted cell suspension and transfer it to an 8-well chamber (200 µL/well) with a P200 micropipette 
189| Incubate the 8-well chamber at 30 ˚C for 30 min. 
        CRITICAL The chamber containing C. albicans cells must be handled carefully as they will not adhere to the bottom 
of the 8-well chamber as well as the other fungal species. 
?  TROUBLESHOOTING 
General setup of the fluorescence confocal microscope for live-cell imaging ● TIMING 30 min 
190| Switch on the laser(s) and set the stage temperature: 25 ˚C for N. crassa; 28 ˚C for F. oxysporum; 30 ˚C for C. 
neoformans and C. albicans; 37 ˚C for A. fumigatus. 
191| Adjust the WLL laser power to 70 %. 
192| Clean the 63× water immersion objective with lens cleaning tissue. 
193| Set the excitation beam wavelength(s), laser intensity(ies) and emission wavelength(s) as described in the 
Equipment setup section. 
        CRITICAL Due to the high sensitivity of HyD detectors, it is important to set the laser intensity at a low level (~10 %) 
to avoid causing damage to the detectors. 
194| During imaging experiments, place the 8-well chamber on the microscope stage, focus the sample using the 
eyepieces and select the region of interest to image. 
?  TROUBLESHOOTING  
195| Adjust the Z-position as well as gain and offset for each channel. 
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196| At this point, individual images can be acquired or successive images can be recorded in a time course with an 
interval time of 10 seconds. For time-lapse experiments extending over 30 min, we recommend interval times of at 
least 20 s. 
197| Save the experimental data to appropriate folders and export images as .tif files. 
198| Remove the sample and clean the objective. Cool down the laser or lasers and switch it or them off. 
 
Live-cell fluorescence imaging of fungal cells using BODIPY-cPAF26 ● TIMING 45 min 
199| Prepare samples as described in steps 163–166 (N. crassa), 167–170 (A. fumigatus), 171–179 (C. neoformans), 
180–182 (F. oxysporum), and 183–189 (C. albicans). 
200| In a 1.5 mL microcentrifuge tube, dilute 2 μL of 5 mM BODIPY-cPAF26 DMSO stock solution with 998 μL of sterile 
dH2O to obtain a 10 µM BODIPY-cPAF26 solution. 
201| Using a P200 micropipette, carefully remove 40 µL of the 200 µL medium from one well of the 8-well chamber, 
which contains the fungal cells. 
202| Add 40 µL of the solution prepared in step 200 to the same well mentioned in the previous step to obtain a 2 µM 
solution of BODIPY-cPAF26. 
203| Incubate the cells with BODIPY-cPAF26 for 10 min at r.t. 
        CRITICAL Cells must be handled carefully to minimize cell detachment from the bottom of the well. 
204| Acquire images as required. Live-cell imaging can be performed for up to 60 min without causing obvious 
deleterious effects on the cells. However, immediate imaging following BODIPY-cPAF26 treatment is highly 
recommended.  
205| After acquisition, save the files to an appropriate location and subsequently back up the files at an appropriate 
time to prevent any data loss. 
206| Discard cells following biological waste disposal regulations. 
  PAUSE POINT After acquisition, images can be analyzed at any time. 
 
Real-time fluorescence imaging of A. fumigatus using BODIPY-cPAF26 ● TIMING 1 h 
       CRITICAL To maximize the localization of BODIPY-cPAF26 at the cell membrane and the quality of the fluorescence 
images, we recommend performing steps 207-217 one well at a time. 
207| Prepare samples as described in steps 167–170. 
208| Prepare a 5 mM DMSO stock solution of the red counterstain (TAMRA-PAF96) using a 1.5 mL microcentrifuge tube 
(4.8 mg in 1 mL DMSO). 
209| In a 1.5 mL microcentrifuge tube, dilute 4 μL of the 5 mM red counterstain DMSO stock solution with 996 μL of 
sterile dH2O to obtain a 20 µM solution of the counterstain. 
210| Using a P200 micropipette, carefully remove 40 µL of the 200 µL medium from a well of the 8-well chamber 
containing the fungal cells. 
211| Add 40 µL of the solution prepared in step 208 to the well referred to in the previous step to obtain a 5 µM final 
concentration of the red counterstain. 
212| Incubate the cells with 5 µM red counterstain for 10 min at r.t. 
213| Using a P200 micropipette, carefully remove 160 µL of the 200 µL medium from the well of the 8-well chamber 
and add 160 µL of a fresh solution of liquid Vogel’s sucrose minimal medium in dH2O (1: 4). 
        CRITICAL Cells must be handled carefully to minimize any cell detachment from the bottom of the well. 
214| Using a P200 micropipette, carefully remove 40 µL of the 200 µL medium from the well of the 8-well chamber and 
place the chamber on the stage of the confocal microscope. 
215| Identify a region of interest containing one or more red-stained cells. Re-adjust the Z-position for optimal focus. 
216| Using a P200 micropipette, gently add 40 µL of the solution prepared in step 200 to obtain a 2 µM solution of 
BODIPY-cPAF26.  
217| Acquire a series of images in a time course (recommended interval time between images: 5 sec).  
?  TROUBLESHOOTING 
218| After acquisition, back up the files to prevent any data loss. 
219| Discard cells following biological waste disposal regulations. 
  PAUSE POINT After acquisition, images can be analyzed at any time. 
 
?  TROUBLESHOOTING 
Troubleshooting advice can be found in Table 8. 
 
  
30 
Table 8. 
 
● TIMING 
Synthesis of m-iodophenyl-BODIPY (3): Steps 1-25 
Steps 1-7, Condensation of 3-iodobenzaldehyde and 2,4-dimethylpyrrole: 23 h 
Steps 8-13, Oxidation: 1 h 
Steps 14-17, BF3·Et2O coordination: 5 h 
Steps 18-22, Work-up: 1 h 
Steps 23-25, Purification: 2 h 
Synthesis of Fmoc-Trp(C2-BODIPY)-OH (1): Steps 26-35 
Steps 26-31, Fmoc-Trp-OH arylation with compound 3: 1 h 
Steps 32-34, Work-up: 1 h 
Steps 35, Purification: 3 h 
Stability analysis of the amino acid 1: Steps 36-37 
Steps 36-37, HPLC analysis: 1 h 
Solid-phase peptide synthesis of BODIPY-cPAF26: Steps 38-69 
Steps 38-39, Resin preparation: 15 min 
Steps 40-45, Coupling of the first amino acid to the resin: 1.25 h 
Steps 46-47, Fmoc removal: 15 min 
Steps 48-55, Coupling of second amino acid and peptide elongation: 9 h 
Steps 56-62, Coupling of amino acid 1: 1.25 h 
Steps 63-67, Cleavage of the linear protected peptide from the resin: 1 h 
Steps 68-69, Solvent removal from the crude peptide: 24 h 
Peptide cyclization: Steps 70-77 
Steps 70-75, Cyclization of the protected peptide: 3 h 
Steps 76-77, Lyophilization of the cyclic protected peptide: 24 h 
Hydrogenation reaction: Steps 78-84 
Steps 78-82, Hydrogenation reaction: 48 h 
Steps 83-84, Work-up: 1 h 
Purification of the BODIPY-cPAF26 peptide: Steps 85-89 
Steps 85-88, HPLC purification: 3 h 
Step 89, Solvent removal and isolation of BODIPY-cPAF26: 48 h 
Proteolytic stability of BODIPY-cPAF26 and PAF26 peptides: Steps 90-94 
Steps 90-92, Sample preparation: 1 h 
Steps 93-94, Incubation and HPLC analysis: 24 h 
Fluorogenic response of BODIPY-cPAF26 in phospholipid membranes: Steps 95-106 
Steps 95-101, Sample preparation: 1 h 
Steps 102-106, Spectroscopic measurements: 30 min 
Cytotoxicity of BODIPY-cPAF26 in A549 human lung epithelial cells: Steps 107-131 
Steps 107-118, Cell counting and plating: 1 h 
Steps 119-120, Overnight cell incubation: 16 h 
Steps 121-123, Preparation of BODIPY-cPAF26 and control solutions: 1 h 
Steps 124-125, Incubation of cells with compounds: 4 h 
Steps 126-131, MTT cell viability assay: 20 h 
Culture of fungal species: Steps 132-151 (can be performed in parallel) 
Steps 132-135, Culture of N. crassa: 121 h 
Steps 136-140, Culture of A. fumigatus: 73 h 
Steps 141-142, Culture of C. neoformans: 73 h 
Steps 143-149, Culture of F. oxysporum: 121 h 
Steps 150-151, Culture of C. albicans: 73 h 
Antifungal activity measurements of BODIPY-cPAF26 and PAF26 peptides in N. crassa and A. fumigatus: Steps 152-
162 
Steps 152-153, Peptide dilutions: 30 min 
Steps 154-160, Plate preparation: 1 h 
Steps 161-162, Overnight incubation and measurements: 24.5 h 
Preparation of fungal cells for live-cell fluorescence imaging: Steps 163-189 (can be performed in parallel) 
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Steps 163-166, Preparation of N. crassa cells: 4.5 h 
Steps 167-170, Preparation of A. fumigatus cells: 25 h 
Steps 171-179, Preparation of C. neoformans cells: 21.5 h 
Steps 180-182, Preparation of F. oxysporum cells: 9 h 
Steps 183-189, Preparation of C. albicans cells: 13.5 h 
General setup of the fluorescence confocal microscope for live-cell imaging: Steps 190-198 
Steps 190-198, Microscope set-up: 30 min 
Live-cell fluorescence imaging of fungal cells using BODIPY-cPAF26: Steps 199-206 
Steps 199-202, Sample preparation: 15 min 
Steps 203-206, Incubation of BODIPY-cPAF26 and image acquisition: 30 min 
Real-time fluorescence imaging of A. fumigatus using BODIPY-cPAF26: Steps 207-219 
Steps 207-213, Sample preparation and incubation of counterstain: 30 min 
Steps 214-219, Incubation of BODIPY-cPAF26 and image acquisition: 30 min 
 
ANTICIPATED RESULTS 
 
Chemical properties of amino acid 1 and peptide BODIPY-cPAF26. Both 1 and the BODIPY-cPAF26 display excitation 
and emission maximum wavelengths in the green region of the visible spectra (λexc. ~ 500 nm, λem. ~ 520 nm), which 
makes the use of these compounds compatible with GFP/FITC filters in most equipments (Figure 3). BODIPY-cPAF26 
displays strong fluorogenic behavior, with quantum yields over 30 % in phospholipid membranes and negligible 
fluorescence in aqueous media, as proven by experiments conducted by our group (see Figure 12). BODIPY-cPAF26 is 
also expected to display a high affinity for fungal cells (see Figures 5b and 5c), high proteolytic stability (see 
Supplementary Figure 3) but its presence should not affect the viability of, for instance, human cells (Figure 5d).  
 
Fluorescence live-cell imaging of fungal cells and real-time imaging of A. fumigatus using the peptide BODIPY-
cPAF26. We successfully employed the peptide BODIPY-cPAF26 for confocal fluorescence imaging of several fungal 
pathogens, including N. crassa, A. fumigatus, C. neoformans, F. oxysporum and C. albicans. The fluorogenic behavior of 
BODIPY-cPAF26 is expected to enable direct live-cell imaging by simple incubation of the peptide with the fungal cells, 
in a single step and without the need for any washing (Figure 6). We also performed real-time imaging experiments 
using BODIPY-cPAF26 in A. fumigatus (Figure 7). Time-course fluorescence imaging at high magnification show staining 
of the cells a few seconds after the addition of BODIPY-cPAF26 to the media, and its preferential localization in the 
fungal cell membranes.  
 
Analytical data 
 m-iodophenyl-BODIPY (3). 
Red powder, 234 mg (98 % purity, 24 % yield). HPLC tR = 8.0 min (Gradient_2, Table 4). 
1H NMR (CDCl3, 400 MHz): δ 7.76 (dt, J = 7.7, 1.5 Hz, 1H), 7.62 (t, J = 1.6 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.19 – 7.14 (m, 1H), 
5.92 (s, 2H), 2.48 (d, J = 1.3 Hz, 6H), 1.36 (s, 6H).  
13C NMR (CDCl3, 100 MHz): δ 155.9, 142.9, 139.3, 138.0, 137.1, 136.8, 130.7, 127.3, 121.5, 94.3, 14.7, 14.6 (one 
quaternary carbon signal not seen).  
HRMS (m/z): [M+H]+ calcd. for C19H18BF2IN2, 451.0654; found: 451.0651. 
 
Fmoc-Trp(C2-BODIPY)-OH (1). 
Red powder, 122 mg (> 99 % purity, 56% yield). HPLC tR = 7.0 min (Gradient_2, Table 4). 
1H NMR (CDCl3, 400 MHz): δ 8.12 (s, 1H), 7.69 – 7.56 (m, 4H), 7.48 (t, J = 7.7 Hz, 1H), 7.41 (t, J = 1.7 Hz, 1H), 7.37 (d, J = 
4.9 Hz, 2H), 7.30 (t, J = 8.0 Hz, 3H), 7.25 – 7.21 (m, 1H), 7.20 – 7.13 (m, 3H), 7.07 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 5.90 (s, 
1H), 5.87 (s, 1H), 5.09 (d, J = 8.0 Hz, 1H), 4.55 (d, J = 7.5 Hz, 1H), 4.17 (q, J = 10.3, 9.4 Hz, 2H), 4.01 (s, 1H), 3.44 – 3.37 
(m, 1H), 3.37 – 3.28 (m, 1H), 2.47 (s, 3H), 2.46 (s, 3H), 1.38 (s, 3H), 1.35 (s, 3H).  
13C NMR (CDCl3, 100 MHz): δ 174.8, 163.1, 156.0, 155.9, 143.9, 143.2, 141.4, 140.7, 136.1, 136.0, 135.1, 133.9, 131.5, 
130.1, 129.1, 128.8, 127.9, 127.8, 127.2, 125.2, 123.2, 121.6, 120.5, 120.1, 119.3, 111.2, 108.2, 67.2, 47.2, 36.9, 28.0, 
14.8, 14.7.  
HRMS (m/z): [M+Na]+ calcd. for C45H39BF2N4O4, 771.2930; found: 771.2925. 
 
H-Arg(NO2)-Lys(Z)-Lys(Z)-Trp(C2-BODIPY)-Phe-Trp-Gly-OH. 
Red powder, 61 mg (90 % purity, 75 % yield). 
HPLC-MS (m/z): [M+H]+ calcd for C86H98BF2N17O14, 1642.6, found 1643.2.  
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Cyclo(Arg(NO2)-Lys(Z)-Lys(Z)-Trp(C2-BODIPY)-Phe-Trp-Gly). 
Red powder, 53 mg (88 % purity, 77 % yield). 
HPLC-MS (m/z): [M+H]+ calcd for C86H96BF2N17O13, 1624.6, found 1626.2. 
 
BODIPY-cPAF26 peptide. 
Crude form: red powder, 25 mg (85 % purity, 58 % yield) 
Pure form: red powder, 9.2 mg (> 99 % purity, 25 % yield). HPLC tR = 5.8 min (Gradient_1, Table 4).  
1H NMR (CD3OD, 600 MHz): δ 8.55 (s, 3H), 7.89 – 7.84 (m, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.60 – 7.55 
(m, 2H), 7.42 (dt, J = 8.1, 0.9 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.18 – 7.12 (m, 5H), 7.11 (s, 1H), 7.06 (m, 3H), 6.94 (m, 1H), 
6.10 (s, 1H), 6.06 (s, 1H), 4.45 (t, J = 7.4 Hz, 1H), 4.32 (d, J = 10.5 Hz, 1H), 4.25 (m, 1H), 4.17 – 4.07 (m, 2H), 4.04 (d, J = 
16.5 Hz, 1H), 4.00 (m, 1H), 3.63 (dd, J = 14.9, 9.5 Hz, 1H), 3.51 – 3.45 (m, 1H), 3.38 (m, 1H), 3.30 (1H), 3.27 – 3.23 (m, 
2H), 3.15 (dd, J = 14.2, 7.5 Hz, 1H), 3.10 (dd, J = 14.0, 5.9 Hz, 1H), 2.90 (td, J = 8.6, 4.2 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 
2.63 (dd, J = 14.2, 8.5 Hz, 1H), 2.51 (s, 3H), 2.50 (s, 3H), 2.09 – 1.88 (m, 4H), 1.76 (m, 1H), 1.67 (m, 3H), 1.52 (m, 7H), 
1.48 – 1.41 (m, 4H), 1.37 (m, 2H), 1.26 – 1.14 (m, 2H).  
HRMS (m/z): [M+H]+ calcd for C70H85BF2N16O7, 1311.6926, found 1311.6864. 
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Figure Legends 
Figure 1. Flowchart outlining all the experimental procedures described in this protocol, which 
includes chemical synthesis (yellow), in vitro characterization (blue), and fluorescence imaging 
assays (red). 
Figure 2. Retrosynthetic analysis of the amino acid Fmoc-Trp(C2-BODIPY)-OH (1). 
Figure 3. Synthesis and chemical characterization of amino acid Fmoc-Trp(C2-BODIPY)-OH 
(1). a) Preparation of the amino acid 1 from Fmoc-Trp-OH (2) and m-iodophenyl-BODIPY (3). b) 
Spectral properties of the amino acid 1. c) Long-term stability (as determined by HPLC analysis) of 
the amino acid 1 as solid and in solution (0.1 M) at different temperatures. *: determined after 
redissolvement due to solvent evaporation. 
Figure 4. Synthetic scheme for the preparation of BODIPY-cPAF26 on solid-phase. 
Figure 5. BODIPY-cPAF26, a fluorogenic peptide with high affinity for fungal cells. a) 
Chemical structure of BODIPY-cPAF26. b) Cell viability plots and non-linear regressions for 
BODIPY-cPAF26 and unlabeled PAF26 in N. crassa. Both peptides were incubated at the same 
concentrations with N. crassa conidia, and after 24 h at 25 ºC fungal growth was determined by 
measuring the optical density at 610 nm. Data represented as means ± s.d. (n=3). c) Fluorescence 
spectra of BODIPY-cPAF26 after incubation with liposome suspensions of PC: cholesterol (7:1) in 
PBS ranging from 3.75 mg mL-1 to 0.007 mg mL-1 of PC in 2-fold serial dilutions, λexc.: 450 nm. d) 
Viability of human lung A549 epithelial cells after incubation with different concentrations of 
BODIPY-cPAF26. Individual data points represented together with means ± s.d. (n=4). Non-
significant (n.s.) differences (p > 0.05) were found between untreated cells and any of the treatments.  
  
35 
Figure 6. Confocal live-cell images (top: fluorescence, bottom: bright field) of different fungal 
species after incubation with BODIPY-cPAF26 (2 µM for a-d, 10 µM for e,) for 10 min, without 
any washing steps. a) N. crassa, b) A. fumigatus, c) C. neoformans, d) F. oxysporum and e) C. 
albicans. λexc.: 496 nm, λem.: 505-550 nm. Scale bar: 10 µm. 
Figure 7. Time-course fluorescence imaging of A. fumigatus with BODIPY-cPAF26. High-
resolution fluorescence confocal images of the fungal pathogen A. fumigatus after incubation with a 
cell membrane counterstain (red) and following direct addition of BODIPY-cPAF26 (2 µM, green) 
without any washing steps. BODIPY-cPAF26 initially interacts rapidly with the apical plasma 
membrane of A. fumigatus, its staining moves then towards the base of the germling cell within a few 
minutes (see Supplementary Video 1). λexc.: 496 nm, λem.: 505-550 nm (green); λexc.: 570 nm, λem.: 
585-650 nm (red). Scale bar: 5 µm. 
Figure 8. Time-course illustration of the reaction set-up for the synthesis of compound 3 under 
N2 atmosphere. a) Addition of anhydrous DCM. b) Addition of 2,4-dimethylpyrrole. c) Solution 
resulting after addition of TFA. d) Slow addition of DDQ. e) Addition of BF3·OEt2 to the TEA-
containing mixture. f) Isolated pure compound 3. 
Figure 9. Time-course illustration of the reaction set-up for the synthesis of the amino acid 1. a) 
Reaction vessel after microwave irradiation. b) Filtration of the crude reaction through Celite under 
vacuum. c) Crude mixture prior to purification. d) Isolated pure amino acid 1. 
Figure 10. Setup for the solid-phase synthesis of BODIPY-cPAF26. a) Manifold for manual 
SPPS. b) Experimental set-up for resin cleavage. c) Crude protected peptide after lyophilization. 
Figure 11. Experimental setup for the hydrogenation of the cyclic protected peptide. a) Purge 
under N2 stream. b) Hydrogenation reaction under H2 at atmospheric pressure. c) Filtration of crude 
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solution of the reaction mixture through a glass Pasteur pipette. d) Pure BODIPY-cPAF26 after 
semi-preparative HPLC purification. 
Figure 12. Pictograms of BODIPY-cPAF26 and fluorescein under excitation with 365 nm light 
using a hand-held UV lamp. a) BODIPY-cPAF26 (10 μM) in high concentration of liposomes (1.8 
mg mL-1). b) BODIPY-cPAF26 (10 μM) in low concentration of liposomes (0.03 mg mL-1). c) 
BODIPY-cPAF26 (10 μM) in DPBS. d) Fluorescein (4 μM) in basic EtOH. 
Figure 13. Pictogram of A549 cells in a 96-well plate after detergent incubation. Cells were 
incubated in four replicates with different concentrations of BODIPY-cPAF26 (rows B-E) as well as 
full DMSO (row F) and DPBS (row G) for positive and negative controls, respectively. 
Figure 14. Plate layout for the antifungal activity assays. a) Steps 154–156. b) Step 157. c) Step 
158. d) Step 160. Conidia are incubated in six replicates with different concentrations of peptide 
(rows A-C and E-G) and controls without peptide (column 12). In addition, ‘blank’ wells contain 
Vogel’s sucrose minimal medium only (rows D and H). 
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Tables 
Table 1. Composition of Vogel’s trace element solution (store at 4 oC for up to 12 months) 
Citric acid · H2O 5 g 
ZnSO4 · 7 H2O 5 g 
(NH4)2Fe(SO4)2 · 6 H2O 1 g 
CuSO4 · 5 H2O 250 mg 
MnSO4 · H2O 50 mg 
H3BO3 50 mg 
Na2MoO4 · 2H2O 50 mg 
dH2O To a total volume of 1 L 
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Table 2| Composition of Vogel’s salts 50X stock solution (store at 4 oC for up to 12 months). 
Sodium citrate · 2 H2O 127 g 
KH2PO4 250 g 
NH4NO3 100 g 
MgSO4 · 7 H2O 10 g 
CaCl2 · 2 H2O 5 g 
Vogel’s trace element solution 
(see Table 1) 
5 mL 
Biotin solution (0.5 % (w/v) of 
d-biotin in dH2O) 
5 mL 
dH2O To a total volume of 1 L 
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Table 3| Composition of solid Vogel’s sucrose minimal agar medium (store at 4 oC for up to 12 months). 
Vogel’s salts 50X stock 
solution (see Table 2) 
20 mL 
Sucrose 20 g 
Agar 20 g 
dH2O To a total volume of 1 L 
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Table 4| HPLC conditions for the analysis of crude mixtures and purified compounds. 
Equipment HPLC 
Column XBridge BEH 130 C18 reverse-phase column 
4.6 × 100 mm (3.5 µm) 
Solvents A: H2O (0.045 % TFA (v/v)) 
B: ACN (0.036 % TFA (v/v)) 
Flow rate 1 mL min-1 
Gradient_1 5-100% (v/v) B over 8 min; 100% (v/v) B over 3 min; 
100-5% (v/v) B over 0.5 min; 5% (v/v) B over 3 min 
Gradient_2 50-100% (v/v) B over 8 min; 100% (v/v) (v/v) B over 
3 min; 100–50% (v/v) B over 0.5 min; 50% (v/v) B 
over 3 min 
Injection volume 2-15 µL 
Detection wavelengths 210-400 nm 
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Table 5| HPLC-MS conditions for the analysis of crude mixtures and purified compounds. 
Equipment HPLC-MS (1) HPLC-MS (2) 
Column Phenomenex Gemini C18 110A reverse-phase column, 
4.6 x 50 mm (particle size 3.5 µm) 
XSelect CSH C18 reverse-phase column, 4.6 x 50 mm 
(particle size 3.5 µm) 
Solvents A: H2O (0.1 % FA (v/v)) 
B: ACN (0.1 % FA (v/v)) 
A: H2O (0.1 % FA (v/v)) 
B: ACN (0.07 % FA (v/v)) 
Flow rate 1 mL min-1 2 mL min-1 
Gradient 0-100% (v/v) B over 8 min; 100 %(v/v) over 3 min; 100–
0% (v/v) B over 0.5 min; 0% (v/v) B over 2.5 min 
5-100% (v/v) B over 4.5 min; 100 % over 1.5 min; 100–5% 
(v/v) B over 0.1 min; 5% (v/v) B over 0.4 min  
Injection volume 10-50 µL 2-15 µL 
Detection wavelengths 210-600 nm 210-400 nm  
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Table 6| Semi-preparative HPLC conditions for the purification of compounds. 
Column Jupiter C12 reverse-phase column 
21.2 × 100 mm (10 µm), Proteo 90 Å, Ax (Phenomenex) 
Solvents A: H2O (0.1 % TFA (v/v)) 
B: ACN (0.05 % TFA (v/v)) 
Flow rate 16 mL min-1 
Gradient 0-35% (v/v) B over 5 min; 35-55% (v/v) B over 18 min; 100–0% (v/v) B 
over 1 min; 0% (v/v) B over 1 min 
Injection volume 500 µL 
Detection wavelengths 220 and 310 nm 
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Table 7| Reagents needed for the solid-phase peptide synthesis of BODIPY-cPAF26. 
Resin weight: 45.0 mg Loading capacity: 1 mmol g-1    
Reagent Equivalents Molecular weight Density Quantity 
Fmoc-Gly-OH 1.0 297.3 g mol-1 - 13 mg 
DIPEA 3.0 129.2 g mol-1 0.742 g mL-1 24 µL 
DIPEA 7.0 129.2 g mol-1 0.742 g mL-1 55 µL 
Fmoc-Trp-OH 3.0 426.5 g mol-1 - 57 mg 
Fmoc-Phe-OH 3.0 387.4 g mol-1 - 52 mg 
Fmoc-Lys(Z)-OH 3.0 502.6 g mol-1 - 68 mg 
Fmoc-Arg(NO2)-OH 3.0 441.4 g mol-1 - 60 mg 
DIC 3.0 126.2 g mol-1 0.815 g mL-1 21 µL 
OxymaPure 3.0 142.1 g mol-1 - 19 mg 
Fmoc-Trp(C2-BODIPY)-OH 1.5 748.6 g mol-1 - 51 mg 
PyBOP 1.5 520.4 g mol-1 - 35 mg 
HOBt (hydrate) 1.5 153.1 g mol-1 - 10 mg 
DIPEA 2.0 129.2 g mol-1 0.742 g mL-1 16 µL 
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Table 8 | Troubleshooting. 
 
Step(s) Problem Possible reason Possible solution 
23 Compound 3 is eluted with 
only hexane during column 
chromatography 
Incorrect equilibration of 
the purification system or 
traces of DCM remaining 
after evaporation 
Combine all fractions in a 
round-bottom flask to 
remove the solvent and 
repeat the purification steps 
25 Low recovery yield after 
column chromatography  
Compound 3 co-elutes 
with some byproducts 
Combine impure fractions in 
a round-bottom flask, remove 
the solvent and crystallize 
compound 3 in DCM: hexane 
(1: 6) 
31 Low conversion in the 
formation of compound 1 
Crude impurities or large 
scale may decrease the 
synthetic yield 
Add more Pd(OAc)2 and 
AgBF4 and perform an 
additional microwave 
irradiation cycle 
37 Samples of amino acid 1 in 
solution dry out 
Low boiling point of the 
solvent used 
Re-dissolve the dry sample in 
MeOH and analyze by HPLC-
MS 
54 Positive Kaiser test  Partial amino acid 
incorporation  
Repeat the coupling. 
Alternatively, employ longer 
reaction times (16 h) or 
employ the reaction 
conditions from steps 48-52. 
54, 62 Unclear result in Kaiser 
test  
Partial amino acid 
incorporation or too 
many resin beads used 
for the test  
Repeat the test with fewer 
resin beads. If still unclear, 
cleave a small portion of the 
resin and analyze it by HPLC. 
If the incorporation of the 
amino acid is partial, repeat 
the coupling 
62 Positive Kaiser test  Partial amino acid 
incorporation  
Repeat the coupling using 0.5 
eq. of amino acid 1, HOBt and 
PyBOP and 1 eq. DIPEA  
62 Abnormal color in Kaiser 
test  
The BODIPY fluorophore 
gives intense yellow color 
Repeat the test with fewer 
resin beads 
82  BODIPY-cPAF26 peptide 
not formed and/or 
formation of byproducts 
Low catalyst efficiency Repeat the hydrogenation 
reaction with a different 
source/batch of Pd(OH)2-C 
94 Minor degradation 
observed for PAF26 
Low protease 
concentration 
Increase the pH of the buffer 
to 7.5-7.8 with sodium dibasic 
phosphate to speed up the 
degradation 
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106 No differences in 
fluorescence between 
different liposome 
suspensions  
Wrong concentration of 
BODIPY-cPAF26 or 
liposome suspensions  
Repeat the preparation of the 
liposome dilutions in DPBS, 
ensuring all samples are 
properly vortexed 
106 Fluorescein shows little 
fluorescence emission 
pH of the solution is not 
adequate 
Increase the solution pH with 
basic EtOH (0.1 N NaOH) or 
repeat the sample 
preparation  
111 A549 cells do not detach 
from cell culture flask 
The proteolytic activity of 
trypsin is reduced 
Incubate for longer time (5 
min). Alternatively, wash the 
cells again with 10 mL Ca2+-
free DPBS and use a fresh 
batch of Trypsin-EDTA 
120 A549 cells do not adhere 
to the bottom of the 
plate(s) or there are signs 
of contamination 
Inadequate manipulation 
of the cells 
Discard plate(s) and use a 
fresh batch of cells and 
reagents (i.e. media, DPBS, 
Trypsin-EDTA) 
128 No dark precipitate is 
observed in the cells 
The MTT reaction is slow Incubate the cells for longer 
time, typically another 2 h 
131 Absorbance values are too 
low 
Cell number per cell is too 
low or incubation times 
are too short 
Repeat the experiment with 
more cells per well or 
increase the MTT reagent and 
detergent incubation times 
131 Absorbance values are too 
high 
Cell number per well is 
too high 
Decrease cell density when 
plating 
131 High standard deviation 
between replicates 
Inaccurate plating or 
pipetting 
Increase accuracy of cell 
plating and check the 
performance of pipettes 
133, 138, 
142, 145, 
151 
Fungal cells do not grow 
properly or there are signs 
of contamination 
Fungi in the stock culture 
are dead or mutated. 
Poor microbiological 
technique implemented 
or the recipe of the 
growth medium was not 
followed correctly  
Discard flasks. Prepare new 
cultures using a new batch of 
medium. Inoculate with a 
fresh stock culture. Check 
that the temperature of 
incubation is correct 
162 High variability in 
absorbance values 
between replicates  
Inaccurate preparation of 
the 96 well-plate  
Confirm the multichannel 
pipette is working well for all 
the channels  
162 Absorbance values are too 
low 
Not enough cells have 
been transferred to the 
96 well-plate 
Gently homogenize the cell 
suspension during plating to 
avoid any cell settling in the 
pipette basin 
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179,189 C. neorformans or C. 
albicans detach from the 
bottom of the chamber 
Sudden movement of the 
chamber  
Discard cells if they have 
been treated with peptide. If 
untreated, leave them in the 
incubator for further 30 min 
and avoid sudden movements 
194 Fluorescence is not 
detected during image 
acquisition 
Laser intensity is too low 
or laser is switched off 
Check the laser is switched on 
and adjust its intensity 
appropriately 
217 Red-stained cell(s) have 
disappeared from the field 
of view after the addition 
of BODIPY-cPAF26 
Cells have detached 
during the addition of 
BODIPY-cPAF26 
Move to another well and, 
when gently adding BODIPY-
cPAF26, place the pipette tip 
close to the surface of the 
medium to minimize any 
movement generated by 
impact of the droplet 
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Additional information 
Supplementary Information is available in the online version of the paper. 
Supplementary Figure 1.  
Supplementary Figure Legend 1. Analysis of the long-term stability of the amino acid 1 when 
stored as a solid at different temperatures. HPLC-MS traces of the amino acid 1 after being stored 
in the dark for 4 months at r.t., 4 ºC, and -20 ºC. UV detection: 500 nm. 
Supplementary Figure 2.  
Supplementary Figure Legend 2. Analysis of the long-term stability of the amino acid 1 when 
dissolved in organic solvents at different temperatures. HPLC-MS traces of the amino acid 1 after 
being stored in the dark for 4 months in: a) DCM at -20 ºC, b) MeOH at 4 ºC, c) DMF at r.t. In c), 
the green arrow points at the remaining amino acid 1 and the main peaks correspond to Fmoc-
removed side products. UV detection: 500 nm. 
Supplementary Table 1. Cellular activity of BODIPY-cPAF26 and PAF26 in different fungal 
species. Cell viability was measured after 16 h incubation with different concentrations of BODIPY-
cPAF26 or PAF26 peptides at 25 ˚C for N. crassa or 37 ˚C for A. fumigatus. IC50 values (µM) are 
represented as means ± s.d. (n=3). 
Supplementary Table 2. Fluorescence quantum yields of BODIPY-cPAF26 in PC: cholesterol 
(7: 1) liposome suspensions in PBS with increasing hydrophobicity. PBS alone was used as a 
negative control. Quantum yields were determined by comparing the integrated emission area of the 
fluorescence spectra to the emission area of fluorescein in basic EtOH (QY: 0.97), λexc.: 450 nm. 
Data represented as means ± s.d. (n=3). 
Supplementary Figure 3. 
Supplementary Figure Legend 3. Time-course analysis of the chemical integrity of BODIPY-
cPAF26 and unlabeled linear PAF26 in proteolytic environments. HPLC traces of BODIPY-
cPAF26 (a) and unlabeled PAF26 (b) before incubation (top) and after incubation (bottom) at a 
  
48 
concentration of 200 µM in a protease cocktail (1 mg L-1). Green arrows point at the peaks of intact 
BODIPY-cPAF26 and red arrows point at intact PAF26. UV detection: 280 nm. Purities were 
determined by integration of the peak areas in respective HPLC chromatograms at 280 nm.  
Supplementary Figure 4. 
Supplementary Figure Legend 4. Electrospray analysis of BODIPY-cPAF26 and unlabeled 
PAF26 after 24 h incubation in a protease cocktail. Both peptides (200 µM) were incubated in 1 
mg L-1 of the protease cocktail, and their respective mass spectra were recorded on a Waters 
Micromass ZQ mass spectrometer (ESI positive mode). a) MS analysis of BODIPY-cPAF26 (exact 
mass: 1311 Da). b) MS analysis of unlabeled PAF26 (exact mass: 949 Da). 
Supplementary Video 1.  
Supplementary Video Legend 1. Time-course high-resolution imaging of A. fumigatus upon 
treatment with BODIPY-cPAF26. A. fumigatus were pre-treated with a cell membrane counterstain 
(red) and imaged under the confocal microscope. Cells were then treated with BODIPY-cPAF26 (2 
µM, green) and further imaged without any washing steps. The movie shows the rapid fluorogenic 
response of BODIPY-cPAF26 upon interaction with the cell membrane of A. fumigatus. Scale bar: 5 
µm. 
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